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2 CHAPTER 1 
Introduction 
Overview 
 The purpose of this dissertation was to explore the associations of sense of 
belonging and hope with medication adherence in persons with schizophrenia. While the 
literature on medication non-adherence in persons with schizophrenia is extensive, literature 
exploring how medication-taking behaviors may be impacted by hope and sense of belonging is 
limited to non-existent in this population. Exploration of sense of belonging and hope in 
schizophrenia has potential to provide new understanding of positive factors influencing 
medication adherence in this population of often chronically ill individuals. The knowledge 
gleaned from this study may subsequently guide future interventional research to impact the 
problem of medication non-adherence in schizophrenia that, although well studied, has no 
consistently effective strategies for improvement in place (Velligan et al., 2009). This 
dissertation study will provide initial data about relationships between medication adherence and 
sense of belonging and hope. 
Statement of the Problem 
Schizophrenia affects approximately 3.5 million people in the United States (Jablensky, 
2000; National Institute of Mental Health, 2017; Nose, Barbui, & Tansella, 2003; Schizophrenia 
and Related Disorders Alliance of America, 2014). At any given time, somewhere between 50-
90% of these individuals do not adhere to medications as prescribed (Lacro, Dunn, Dolder, 
Leckband, & Jeste, 2002; Lieberman et al., 2005; Nose et al., 2003; D. Novick et al., 2010). This 
lack of adherence ranges from partial adherence to the medication regimen to complete non-
adherence. For the purposes of this research, medication adherence is taking 80% or greater of 
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the medication prescribed as reported by the person. This definition is per recommendations by 
expert consensus guidelines on medication adherence problems in schizophrenia and other 
chronic and severe mental illnesses (Velligan et al., 2009). Non-adherence is any deviation from 
the prescribed medication regimen that results in taking less than 80% of prescribed medications, 
as reported by the patient, and includes partial and full non-adherence. 
Medication adherence challenges are not unique to schizophrenia, but the rates of 
medication non-adherence are higher in schizophrenia in comparison to other chronic medical 
illnesses. Medication non-adherence has been identified as an issue in many chronic medical 
illnesses, including HIV, diabetes, and tuberculosis, and has been studied extensively in various 
populations. In a quantitative review of 50 years of research, rates of adherence in various 
chronic medical conditions, including HIV, arthritis, cancer, cardiovascular diseases and others, 
ranged between 74-88% (Kane, Kishimoto, & Correll, 2013). In this same review, psychotic 
disorders were reported to have rates of adherence to the medication regimen as low as 61% 
(Kane et al., 2013).  
There are unique challenges for persons with schizophrenia in adhering to their 
medication regimen including disease-related symptoms such as lack of insight, problematic side 
effects of medications, and the stigma associated with such a severe mental illness. There are 
also unique challenges to the study of medication adherence in schizophrenia, including such 
issues as varying definitions of adherence, symptomology of the disease affecting study 
participation, and accuracy of measurement tools. These challenges complicate identification of 
specific factors that influence adherence and that can be consistently targeted to increase 
adherence rates. 
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Medication non-adherence in schizophrenia often is problematic at the onset of the 
disease and continues with increasing prevalence as the illness progresses. Non-adherence rates 
in the first 12 months of follow-up after experiencing a first psychotic break have been estimated 
between 53% - 59% (Acosta et al., 2009; Coldham, Addington, & Addington, 2002). Recent 
literature indicates widely varying non-adherence among persons with schizophrenia with studies 
reporting non-adherence rates between 12-74% (Garcia et al., 2016; Lacro et al., 2002; 
Lieberman et al., 2005; D. Novick et al., 2010). One observational study that compared 
discontinuation rates of different types of antipsychotics over time found that approximately 90% 
of patients discontinued medication, regardless of type, over a one-year period (Mullins, Obeidat, 
Cuffel, Naradzay, & Loebel, 2008). 
Factors Influencing Adherence Behaviors in Schizophrenia.  
Adherence behaviors in schizophrenia have been poorly understood since study was first 
undertaken on this phenomenon in the 1970s (Lehmann, 1975), almost as long as medications 
have been in existence for the illness. Researchers from that time drew heavily on the existing 
knowledge base of factors influencing non-adherence in other chronic illness populations, even 
though it was estimated that rates of non-adherence in schizophrenia were as much as 20% 
higher than general medical practice populations (Amdur, 1979).This higher rate of non-
adherence suggests that something is different about non-adherence in schizophrenia compared 
to other chronic illnesses. In the infancy of this research, primary factors that were identified as 
contributing to noncompliance (referred to in current literature as nonadherence) included 
complexity of prescription, interference with daily habits, hostile patient attitude, social isolation, 
poor education, lack of motivation, and even the desire of the patient to remain crazy, among 
others (Amdur, 1979; Lehmann, 1975; Van Putten, 1976). 
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Since that preliminary period of inquiry into the phenomenon, medication non-adherence 
in schizophrenia has been more extensively studied. Additional factors influencing medication 
non-adherence have been suggested, while some of the factors initially identified continue to be 
shown to play a role. In a review of the literature in the later part of the 1990s,  compliance was 
found to be associated with multiple factors including illness characteristics, cognition/memory, 
insight, health beliefs, perceived benefit of medications, alcohol use, substance abuse, 
medication dosage/route and side effects, family and social support, and relationship with the 
provider (Fenton, Blyler, & Heinssen, 1997).  
In the years since the literature review by Fenton et. al., (1997), there have been little 
additional findings that have enhanced the body of literature or aided development of strategies 
proven to decrease non-adherence rates. In a more recent systematic review on medication 
adherence in schizophrenia, Medic et. al. (2013), identified fourteen factors in the literature as 
having an association with non-adherence. Of the factors identified, the majority had conflicting 
findings in the literature (Medic et al., 2013). Throughout the literature, consistent findings with 
clinical significance are few, and prevalence rates of non-adherence in this population remain 
largely the same (Amdur, 1979, M. J. Byerly, Nakonezny, & Lescouflair, 2007; Fenton et al., 
1997; Medic et al., 2013). This indicates that other approaches are needed to understand the 
phenomenon and to develop interventions to decrease prevalence rates.  
It is noteworthy that medication route, specifically oral medications versus long-acting 
injectable medications, has been repeatedly identified to be associated with medication 
adherence. One study found that individuals diagnosed with schizophrenia taking injectable 
medications were 43 times more likely to be adherent than those taking oral medications (Acosta 
et al., 2009). This may be related to the individual only passively participating in receipt of 
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medications because the nurse is responsible for administering the medication to the patient. This 
indicates a need to specifically study patients who self-manage oral medications to enable a 
clearer understanding of potential factors influencing adherence behaviors un-confounded by 
passive medication taking behaviors.  
Sense of belonging and hope as potential factors influencing adherence behaviors. 
Schizophrenia causes alterations in a person’s cognition, perceptions of reality, and social 
interactions with others, often preventing full participation in work, school and/or family 
activities even during periods of stable symptoms of the disease (Sergi et al., 2007). These social 
and relational deficits are further exacerbated when the individual is not adherent to prescribed 
medication to manage symptomatology of the illness. Additionally, acute symptoms of 
schizophrenia often produce behaviors and experiences that are outside of social norms and 
result in stigma and marginalization that further impede social functioning (Wahl, 2012). These 
behavioral and environmental conditions likely contribute to the social isolation, loneliness, lack 
of sense of belonging, and hopelessness that are commonly experienced by persons with this 
disorder.  
Loneliness and hopelessness are associated with decreased quality of life (QOL) and 
identified as roadblocks to recovery (Hayhurst, Drake, & Lewis, 2010; White, McCleery, 
Gumley, & Mulholland, 2007). Decreased QOL has been linked with medication non-adherence 
and relapse in schizophrenia (Hayhurst et al., 2010), which may indicate that other interpersonal 
factors such as a lack of sense of belonging or hopelessness also play a role in medication non-
adherence. The obverse of these psychological states, i.e. having a sense of belonging and hope 
for the future, may result in a more positive psychological state in which patients are more likely 
to be medication adherent due to feelings of being a part of something and enhanced future 
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orientation. In a preliminary qualitative study conducted by this researcher, sense of belonging 
and hope were found to be important in this population, with suggested links to medication 
adherence that warrant further exploration (Barut, Dietrich, Zanoni & Ridner, 2016). 
A factor that may influence a person’s sense of belonging and/or adherence to 
medications is the relationship between the patient and the provider, also referred to as the 
therapeutic alliance. Therapeutic alliance has been linked to medication adherence (Day et al., 
2005; Fenton et al., 1997; Lacro et al., 2002; Leutwyler, Fox, & Wallhagen, 2013; Misdrahi, 
Petit, Blanc, Bayle, & Llorca, 2012), and it has been suggested that the development of a 
therapeutic relationship in the first six months of treatment predicts adherence at six months 
(Frank & Gunderson, 1990). Hagerty and Patusky (2003), who have studied sense of belonging 
in multiple populations, suggest that a sense of belonging can be engendered within the 
therapeutic relationship between the nurse and the patient. However, sense of belonging has not 
been well-studied in schizophrenia, and no literature was identified exploring possible links 
between sense of belonging and therapeutic alliance.  
Exploration of defining attributes of sense of belonging and therapeutic alliance suggests 
inter-relatedness of these concepts (Hagerty, Lynch-Sauer, Patusky, Bouwsema, & Collier, 1992; 
Hougaard, 1994; Misdrahi et al., 2012). Therapeutic alliance has been defined as a relationship in 
which the patient feels understood by the provider (Misdrahi et al., 2009), and feelings of being 
understood are also described in the experience of having a sense of belonging (Hagerty et al., 
1996). A review of the literature on adherence in schizophrenia found that one of the most 
frequently reported factors influencing adherence behaviors was the relationship with the 
physician; 41-60% of adherent patients reported experiencing positive aspects of the therapeutic 
alliance (Day et al., 2005; Medic et al., 2013). This suggests that is likely that the existence of a 
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strong therapeutic alliance will affect both sense of belonging and adherence behaviors in 
patients with schizophrenia. Therefore, to examine the relationship between medication 
adherence and sense of belonging, it will be necessary to control for the influence of the 
therapeutic relationship to avoid any potential interactive effects.  
Statement of Problem Summary 
Medication non-adherence is unmistakably an issue of significance in persons diagnosed 
with schizophrenia. Despite the variability in estimated prevalence of medication non-adherence 
in schizophrenia, it is clear the incidence is high and exceeds non-adherence rates in other 
chronic illness populations. While some factors influencing medication adherence in 
schizophrenia have been well studied in the past several decades, knowledge about other factors 
that can be targeted to effectively and consistently increase rates of medication adherence is 
limited. Existing treatment methods based on current models of adherence are insufficient. In 
order to effectively address this problem, research is needed to increase knowledge of factors 
that consistently promote medication adherence and thereby improve outcomes in this 
population. Additionally, new factors need to be explored, since what is currently known about 
factors that influence adherence in schizophrenia has not impacted the problem of high rates of 
medication non-adherence.  
Significance of the Issue 
Significance to Society.  
Schizophrenia is a leading cause of disability in the United States and worldwide, with 
approximately 1.1% of the world population or 51 million people at any given time diagnosed 
with the disorder (National Institute of Mental Health, 2017). Three and a half million of these 
individuals are in the United States (Jablensky, 2000; National Institute of Mental Health, 2014; 
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Nose et al., 2003; Schizophrenia and Related Disorders Alliance of America, 2014). This equates 
to a little over 7 people per 1,000 or 21,000 people per a city of 3 million in the United States 
(Nemade & Dombeck, 2006). The impact of untreated disease is greater than the rates of illness, 
partially due to illness burden, suffering, and elevated comorbidity and mortality rates (Rice, 
1999; Schoepf, Uppal, Potluri, & Heun, 2014).  
Financial costs of medication non-adherence in schizophrenia. Healthcare costs are 
disproportionally high for the subset of the population with schizophrenia. It is estimated that 
overall annual national health expenditures in developed countries related to schizophrenia are 
approximately 1.1 – 3.5% of total health care expense and comprise 22% of the costs of all 
mental illnesses (Charrier, Chevreul, & Durand-Zaleski, 2013; Rice, 1999; Thieda, Beard, 
Richter, & Kane, 2003). In 2002 in the United States, it was estimated that the overall cost of 
schizophrenia, including direct and non-direct healthcare costs as well as indirect non-healthcare 
costs, was $62.7 billion (Wu et al., 2005). In a more recent analysis in 2013, researchers 
identified the total cost of the illness to be $155.7 billion and included 24% higher excess direct 
health care costs compared to individuals without schizophrenia (Cloutier et al., 2016). It has 
been estimated that 40% of costs associated with treatment for this population are attributed to 
non-adherence (Olivares, Sermon, Hemels, & Schreiner, 2013; Weiden, Kozma, Grogg, & 
Locklear, 2004). This expenditure can have only increased in the ensuing years.  
Most of the costs of schizophrenia are directly related to treatment delivery, particularly 
the expense of hospitalization.  Costs of medications and outpatient follow-up also share a large 
portion of the financial burden. Hospitalization often occurs due to illness relapse, and it has 
been estimated that approximately 75% of relapse occurrences in schizophrenia happen as a 
direct result of medication non-adherence (Caseiro et al., 2012; Olivares et al., 2013). In the U.S. 
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in 2005, the overall cost of hospitalization due to medication non-adherence was estimated to 
range from $1,392 million to $1,826 million, not including additional outpatient or 
pharmaceutical costs (Dilla, Ciudad, & Alvarez, 2013). Schizophrenia has been estimated to be 
the costliest mental illness to treat, partly due to inflated costs resulting from medication non-
adherence (Acosta, Hernandez, Pereira, Herrera, & Rodriguez, 2012; Ascher-Svanum et al., 
2010).  
Violence and incarceration. While violence is not necessarily common in persons with 
schizophrenia, individuals experiencing paranoia, delusions, and other psychotic symptoms, 
which are worsened due to medication non-adherence, may be at elevated risk for violence. This 
increased likelihood of violence in schizophrenia not only results in increased financial and 
psychosocial burden to society, but also impacts individual functioning, QOL and has other 
adverse consequences for the individual and society. Persons who are non-adherent to 
medications are more than twice as likely to be violent compared to their adherent counterparts 
and they have a greater probability of being arrested (Ascher-Svanum, Zhu, Faries, Lacro, & 
Dolder, 2006; Witt, Van Dorn, & Fazel, 2013). Often these arrests are due to behaviors 
influenced by their untreated or undertreated illness and result in incarcerations that are twice as 
long as those without an untreated illness (Torrey et al., 2014). In a prospective longitudinal 
study that followed inmates with schizophrenia after release from prison, it was found that 
schizophrenia was only associated with an increased risk of violence in the absence of treatment 
(Keers, Ullrich, DeStavola, & Coid, 2014). These individuals with untreated or undertreated 
schizophrenia represent approximately 16% of the total jail and inmate population in the United 
States, or close to 319,000 individuals atment (Torrey et al., 2014).  
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Risk of suicide. The risks of harm to self are even greater than the risk of violence in 
schizophrenia, particularly when the illness is not adequately treated. Suicide, a leading cause of 
death in schizophrenia, is increased as much as seven-fold when the person is even partially non-
adherent to medications (Llorca, 2008). Persons with schizophrenia have a greater lifetime risk 
of suicide than the general population; it has been estimated that approximately 5% of persons 
with schizophrenia will commit suicide at some point, with higher prevalence closer to illness 
onset (National Institute of Mental Health, 2017; Palmer et al., 2002). In a systematic review of 
protective and risk factors for suicide in schizophrenia, it was identified that medication non-
adherence was a risk factor for suicide (Hor & Taylor, 2010). Notably, this review found that the 
only consistently identified protective factor against suicide was adherence to medication (Hor & 
Taylor, 2010). 
Impact on families. There are multiple challenges for family members caring for persons 
with schizophrenia, including poor understanding of symptoms of the illness (Magliano et al., 
2000), as well as the impact on the family economically, socially and psychologically. Objective 
and subjective burden on family members was found to be higher in family members of patients 
with schizophrenia compared to family members of patients with other chronic illnesses such as 
heart diseases, renal diseases or diabetes (Magliano et al., 2000). Some of the top identified 
consequences of this burden on family members included decreased family leisure activities, 
increased family conflict, depression among family members, economic difficulties, and 
compromised ability of family members to attend to work, school and other normal life activities 
(Awad & Voruganti, 2004). It has also been reported that family members of patients with 
schizophrenia have lower self-esteem, higher rates of psychological distress, complicated grief 
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and loss, higher rates of primary care utilization, and increased incidence of chronic medical 
conditions (Perlick et al., 2006). 
Summary of Significance to Society.  
A diagnosis of schizophrenia carries a heavy toll for individuals, families and society at 
large, The burden on society is greater due to the direct impact of medication non-adherence 
related to the high costs of treatment for relapse, increased risk of violence, higher rates of 
incarceration, and increased risk of suicide in untreated and undertreated individuals. Medication 
adherence is the only identified protective factor against suicide. Family members are often 
primary care-givers for patients with schizophrenia and often experience the heavy burden of 
medication non-adherence through impaired family dynamics, higher rates of mental and 
medical illnesses, and economic and social impacts. Overall, the cost of medication non-
adherence in schizophrenia to society is high and creates an imperative for solution-finding to 
decrease this burden. 
Significance to Health. 
Medication non-adherence impacts human suffering. Non-adherence in schizophrenia 
has been linked to poorer outcomes, decreased QOL, decreased functioning, increased psychotic 
symptoms, higher rates of illness relapse, and increased number and length of hospitalizations 
(Ascher-Svanum et al., 2006; Knapp, Mangalore, & Simon, 2004; Medic et al., 2013; D. Novick 
et al., 2010; Rittmannsberger, Pachinger, Keppelmuller, & Wancata, 2004). Medication non-
adherence results in increased personal and interpersonal suffering resulting directly from the 
symptoms of the illness. Patients who are non-adherent tend have greater cognitive impairments, 
including conceptual disorganization, decreased attention, stereotyped thinking and memory 
deficits (Acosta et al., 2009). Medication non-adherence also reduces the person’s ability to 
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make significant contributions to society, as persons with the illness may be unable to hold jobs, 
provide for themselves and/or their family members and are otherwise impeded from having 
meaningful life experiences that contribute to greater society.  This decreased QOL is evidenced 
by factors that have been shown to be increased in non-adherent patients, such as higher levels of 
depression and anxiety, cognitive deficits, and acute schizophrenia symptoms, and lower levels 
of social support (Hayhurst et al., 2010). Overall, patients who are non-adherent have more 
severe psychopathology and poorer functional outcomes (Acosta et al., 2009). 
In a study of Medicaid patients, patients with schizophrenia who were non-adherent to 
medications had higher rates of psychiatric hospitalization (59% non-adherent vs. 14% adherent) 
and medical hospitalizations (almost 24% non-adherent vs. 7% adherent) (Gilmer et al., 2004). 
They also have higher usage rates of emergency psychiatric services, higher rates of substance 
abuse, higher risk of homelessness, poorer mental functioning, poorer life satisfaction, and 
poorer health related QOL (Ascher-Svanum et al., 2010; M. J. Byerly et al., 2007; Llorca, 2008). 
Medication non-adherence and psychotic relapse. Relapse, or acute psychotic 
worsening, is highly correlated with medication non-adherence and is of significant overall 
financial cost to society and to the individual (Ascher-Svanum et. al., 2010). The cost of relapse 
to the individual is not only financial, but also physical, mental and emotional. Recurrent 
relapses may lead to increased cognitive decline, exacerbation of comorbid illnesses, 
discouragement and pessimism about the course of the illness, and increased risk of substance 
abuse, criminal behavior, and suicide (Dilla et al., 2013). Additionally, the experience of 
increased psychotic symptoms and being out of touch with reality may cause the individual to 
experience depression, hopelessness and other evidence of emotional distress that decreases 
QOL (Hoffman, Varanko, Gilmore, & Mishara, 2008).  
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Extensive and recurrent relapses have been shown to negatively affect brain integrity in 
persons with schizophrenia, particularly causing brain tissue loss as shown by MRI comparison 
studies (Andreasen, Liu, Ziebell, Vora, & Ho, 2013). There is also indication that psychotic 
relapses may result in decreased capacity for recovery and diminished response to subsequent 
treatment requiring higher medication dosages (Dilla et al., 2013; Remington et al., 2013). With 
repeated relapses, especially when behaviors due to symptoms create conflict in the person’s life, 
the person’s ability to return to school or work decreases and may result in erosion of social 
relationships (Kane et al., 2013). 
Poor management of comorbid illnesses due to medication non-adherence. The general 
life expectancy for persons with schizophrenia is 20-25 years less than the general population, 
largely due to high incidence of medical illnesses such as cardiovascular disease and diabetes 
(Schoepf et al., 2014; Wildgust, Hodgson, & Beary, 2010). While some of this increased 
mortality can be attributed to high incidence of smoking and obesity in persons with 
schizophrenia, it is also related to high rates of non-adherence to smoking cessation and 
diet/exercise programs designed to mitigate risk (Brown, Barraclough, & INSKIP, 2000; 
Wildgust et al., 2010). Similarly, non-adherence to medications prescribed for schizophrenia 
often extends to medications prescribed for comorbid medical illnesses. Compromised medical 
health due to non-adherence to medications further exacerbates the person’s health-related QOL 
and ability to function as a productive member of society.  
Summary of Significance to Health.  
Schizophrenia is a serious and debilitating illness that creates a high degree of human 
suffering, decreases QOL, impairs physical, mental and social health and decreases life 
expectancy. Non-adherence to medications results in increased symptom burden which may 
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decrease life satisfaction and ability of the individual to contribute to society and have 
meaningful life experiences. The risks of illness relapse are higher in non-adherent individuals, 
resulting in repeated exacerbations of acute illness. Higher rates of relapse increase the 
likelihood of lasting effects of schizophrenia including permanent cognitive impairment, 
increased severity of co-morbid medical illnesses and increased risk of suicide. It is estimated 
that there is an average of 28.5 years of life lost directly attributable to this disease burden 
(NIMH, 2017). These health impacts of the illness are lessened when individuals are adherent to 
their medication regimen. 
Significance to Nursing. 
 Role of the staff nurse. Staff nurses, or nurses that provide direct care in psychiatric 
health care settings, have long been assessing the physical and emotional needs of patients and 
then planning and implementing individualized care by using interpersonal techniques (Stuart, 
2014). Hildegard Peplau, known as the ‘mother’ of psychiatric nursing, identified that the heart 
of psychiatric nursing is the nurse’s role as a counselor and that the nurse-patient relationship is 
the bedrock of psychiatric nursing care (Peplau, 1989, 1997). Staff nurses promote mental health 
through a partnership with the patient whereupon they can help the person to identify personal 
health and life goals. Through this partnered therapeutic relationship, personal goal setting, and 
the promotion of medication adherence can occur. The nurse can be an advocate for the patient 
for resource identification to help them achieve medication adherence, as without adherence, 
patients will likely have challenges meeting their goals.  
The psychiatric staff nurse recognizes the patient as a holistic being who makes 
healthcare decisions, including decisions about whether or not to take medications. These 
decisions are often based on individual experiences and interactions with his or her environment 
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(Stuart, 2014). Recognizing this, the nurse can individualize care to address the person’s specific 
needs regarding adherence to medications and empower the person to be an active participant in 
his or her healthcare. Psychiatric nurses play a role in monitoring medication use and may be the 
first healthcare provider to identify signs that the person is not adherent to the medication 
regime. This monitoring and assessment of the nurse can enable early identification of 
medication non-adherence and, if the nurse is equipped with effective intervention strategies, 
may improve medication adherence (Coombs, Deane, Lambert, & Griffiths, 2003). 
Patients may fail to take medications due to fear of medication side effects or upon 
experiencing uncomfortable side effects. Psychiatric nurses have a responsibility to provide 
education and monitor for side effects of medications. When patient concerns about side effects 
arise, the nurses can help with patient with strategies to minimize the effects. The psychiatric 
nurse also provides education about disease process, treatment and medications, and 
consequences of non-adherence (Happell, Manias, & Pinikahana, 2002). This knowledge and the 
nurse’s monitoring and guidance can help patients to integrate consistent medication-taking 
behaviors into their lives. 
The psychiatric nurse is situated to be a primary contact for the families of persons with 
schizophrenia. Family support is very important to medication adherence in persons with 
schizophrenia. However, caregiver burden is high, and caregivers frequently lack education 
about the disease process of schizophrenia which can strain this vital relationship. The 
psychiatric nurse is a key point of contact to promote family members’ engagement and make 
sure they receive individualized psycho-education about the illness, symptoms and treatment. 
This involvement by the nurse can empower family members to support their loved one in 
adhering to the medication regimen (Cohen et al., 2014).  
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 Role of the advanced practice nurse. The advanced practice nurse fulfills all the 
aforementioned roles of assessment, education, and advocacy. The advanced practice nurse also 
fulfills a much-needed role for patients of improving access to psychiatric mental health 
practitioners with medication prescribing authority (Nolan et al., 2012). Due to enhanced skills in 
therapeutic relationship development and respect for the patient as an autonomous, holistic 
being, advanced practice psychiatric nurses have enhanced potential to improve medication 
adherence in patient populations where adherence is a problem (Nolan et al., 2012). Advanced 
practice nurses are highly skilled at seeing the perspective of the patient in adherence issues, as 
well as being effective at educating and garnering support from key support persons to help the 
patient adhere to the medication regimen as prescribed (Nolan et al., 2012). These nurses also 
work in healthcare policy and research settings where they serve to advance knowledge and 
promote policy that support services and environments for patients to be successful in their 
treatment. 
Summary of Significance to Nursing. 
 Psychiatric staff and advanced practice nurses can play a significant role to improve 
medication adherence in persons diagnosed with schizophrenia. These nurses are uniquely 
positioned at multiple intersections of the patient’s healthcare experience, in hospitals, outpatient 
centers and other treatment settings. Knowledge of factors that can impact medication adherence 
can drive targeted nursing interventions and increase the effectiveness of these nurses’ role in 
decreasing the rates of non-adherence.  
Summary of Overall Significance of the Issue 
 Schizophrenia is a leading cause of disability in the United States and worldwide and 
significantly impacts society, health, and the profession of nursing. Many of the detrimental 
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effects of this disease are directly attributable and/or worsened by the high rates of medication 
non-adherence in this population. Increasing medication adherence in persons diagnosed with 
schizophrenia has the potential to greatly decrease the societal burden and human suffering 
caused by the illness. Direct care and advanced practice nurses can play a pivotal role to support 
medication adherence if they are equipped with the right knowledge and interventions that 
influence medication taking behaviors in schizophrenia. 
Purpose of the Study 
 The preceding section identifies the magnitude of the problem of medication non-
adherence in schizophrenia as well as the significance of the issue to society, health and nursing. 
Based on this magnitude and significance, research is needed to identify factors that can decrease 
medication non-adherence. The purpose of this study was to explore the associations of sense of 
belonging and hope with medication adherence, after controlling for therapeutic alliance, in an 
outpatient sample of persons diagnosed with schizophrenia. Additionally, demographic and 
clinical data including the participant’s age, gender, marital status, living situation, employment 
status, and antipsychotic medications were collected for description of the sample.  
Research Questions/Hypotheses 
Study Aim #1:  
Examine the relationship between sense of belonging and medication adherence in persons 
diagnosed with schizophrenia.  
Research Question #1: Controlling for therapeutic alliance, is there an association between 
sense of belonging and medication adherence in persons diagnosed with schizophrenia?  
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Hypothesis #1: Persons diagnosed with schizophrenia who have higher levels of 
sense of belonging will report higher levels of medication adherence than those 
with lower levels of sense of belonging. 
Study Aim #2:  
Examine the relationship between hope and medication adherence in persons diagnosed 
with schizophrenia.  
Research Question #2: Controlling for therapeutic alliance, is there an association 
between hope and medication adherence in persons diagnosed with schizophrenia?  
Hypothesis #2: Persons diagnosed with schizophrenia who have higher levels of 
hope will report higher levels of medication adherence than those with lower 
levels of hope. 
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3 CHAPTER 2  
Conceptual Framework and Literature Review 
Conceptual Framework 
The Theory of Planned Behavior (TPB) guided this study (see Figure 1).  
 
Figure 1. The Theory of Planned Behavior 
TPB has been successfully used to aid understanding of adherence behaviors in 
schizophrenia (De las Cuevas & Peñate, 2015; Holmes, Hughes, & Morrison, 2014; Alex 
Kopelowicz et al., 2007; Lindström & Bingefors, 2000). TPB is a social cognitive model of 
behavior that states that the likelihood of a person engaging in a particular behavior, such as 
adherence, is a function, in part, of subjective norm or perceived social pressure and attitude (I. 
Ajzen, 1991, 2002, 2011; Icek Ajzen & Madden, 1986). Subjective norm is related to the 
person’s belief regarding whether others, particularly loved ones and support persons believe the 
behavior should be performed (Ajzen, 1991).  
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Based on TPB and previously identified factors influencing medication adherence in 
schizophrenia, potential factors influencing medication adherence in schizophrenia were 
identified (see Figure 2).  
 
Figure 2. Potential Factors Influencing Medication Adherence in Schizophrenia 
This conceptual framework, as outlined above, suggests that sense of belonging enhances 
perception of social pressure and attitude towards taking medications and can be measured as 
proxy for subjective norm. Persons who have a greater sense of belonging may be more likely to 
engage in medication adherence due to this subjective norm. Attitude has to do with the person’s 
beliefs about the positive or negative consequences of the behavior (Ajzen, 2002; Ajzen & 
Madden, 1986). Attitude towards medications has been shown to be related to adherence in 
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schizophrenia (De las Cuevas & Peñate, 2015). Persons with greater hope have more insight into 
their illness, may have more positive perceptions of medications and may believe that the 
medication will improve mental health, all of which could increase adherence behaviors. A key 
strength of this framework is that it targets attitudes and insight, both factors that may affect 
hope and have been shown to have some explanatory value related to non-adherence behaviors in 
schizophrenia. Additionally, TPB’s subjective norm construct may account for social contexts, 
family attitudes or social support that result in a sense of belonging and that may influence 
adherence in patients with schizophrenia (Mausbach et al., 2013). 
Critical Analysis of Relevant Literature 
While medication non-adherence in schizophrenia has been identified as a problem since 
the 1970s, much of the literature has studied the same or similar constructs as factors possibly 
impacting medication adherence and there has been little in the way of new direction or focus. 
With the advent of newer second-generation antipsychotics, the climate of medication treatment 
has changed in the ensuing years. Therefore, to better reflect the current environment of 
treatment for medication adherence, this literature review has been limited to approximately the 
last 20 years. Additionally, because this literature review is focused on understanding factors 
associated with medication adherence in schizophrenia and not the effectiveness of interventions, 
interventional studies that targeted medication adherence were excluded. Lastly, it is recognized 
that factors influencing medication adherence may be very different in affective disorders and 
other mental illnesses compared to psychotic disorders. For this reason, studies that included 
mental illnesses outside of the schizophrenia spectrum of disorders (e.g. bipolar disorders, 
depressive disorders, personality disorders) were excluded. Eighteen studies were selected for 
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inclusion in this integrative review of factors influencing medication non-adherence in 
schizophrenia. 
Literature on Factors Influencing Medication Non-adherence in Schizophrenia 
In the schizophrenia research literature, the primary factors identified in the literature 
review as contributing to medication adherence behaviors can be categorized into three groups: 
1). environmental factors, 2). treatment factors, and 3). patient factors (Velligan et al., 2009). 
Primary environmental factors included family and/or social support (Agarwal, Sharma, 
Kumar K. V, & Lowe, 1998; Coldham et al., 2002; Gutierrez-Casares, Canas, Rodriguez-
Morales, Hidalgo-Borrajo, & Alonso-Escolano, 2010; Hudson et al., 2004; Leutwyler et al., 
2013; D. Novick et al., 2010; Olfson et al., 2000; Quach et al., 2009; Rabinovitch, Cassidy, 
Schmitz, Joober, & Malla, 2013; Sapra et al., 2013; Tranulis, Goff, Henderson, & Freudenreich, 
2011).  Social support has been repeatedly found to be associated with medication adherence in 
schizophrenia (Agarwal et al., 1998; Coldham et al., 2002; Gutierrez-Casares et al., 2010; 
Hudson et. al., 2008; Novick et. al., 2010; Olfson et al., 2000; Quach et al., 2009; Rabinovitch et 
al., 2013; Sapra et al., 2013). Coldham et. al. (2002) found that 80% of adherent patients had 
family support compared to 51% in the completely non-adherent group (p=<.001); in other 
words, patients with family support were 1.6 times more likely to be adherent than those without 
family support. Similarly, Gutierrez-Casares et al. (2010) found that patients with low family 
support were more than twice as likely to be non-adherent as those with high family support 
(OR=2.13). Novick et. al. (2010) found that patients who were socially active, as the study 
defined social support, were 1.26 times more likely to be adherent to their medications. 
Definitions of social support vary widely across studies and it may be that different but similar 
constructs are actually being measured.  Social support may also be a component of the broader 
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concept, sense of belonging, which captures the feeling of belonging to a group generated by 
social support. There is no identified research on sense of belonging and medication adherence in 
schizophrenia; however, sense of belonging is a more comprehensive concept that may prove to 
have more explanatory value than social support on its own. Therefore, to capture this broader 
psychological concept, a measure of participants’ sense of belonging was collected for this 
research.  
 Treatment-related factors impacting medication non-adherence included past non-
adherence, medication side effects, medication route (oral vs. injectable), and therapeutic 
alliance with a provider (Acosta et al., 2012; Agarwal et al., 1998; Ascher-Svanum et al., 2006; 
Brain et al., 2013; Gutierrez-Casares et al., 2010; Leutwyler et al., 2013; Misdrahi et al., 2012; 
D. Novick et al., 2010; Olfson et al., 2000; Sapra et al., 2013; Tranulis et al., 2011). Therapeutic 
alliance, or relationship between the patient and the provider, is a factor identified in the 
literature as related to medication non-adherence and may share some similarities with sense of 
belonging that warrant exploration. Misdrahi et. al, (2012) found that in a model with insight and 
substance abuse, therapeutic alliance accounted for 15% of the variance in adherence (r=0,663, 
p<0.0001). Olfson et .al. (2000) measured therapeutic alliance with the Active Engagement Scale 
and found that patients who scored higher on the optimism subscale were 1.5 times more likely 
to be medication adherent. Lastly, Rabinovitch et. al. (2013) found that 35% of the variance in 
adherence was accounted for by therapeutic alliance, and qualitative data suggests that a positive 
trusting relationship with the provider is important to adherence (Leutwyler et. al., 2013; 
Tranulis et. al., 2011) 
Because of the trusting relationship inherent in a therapeutic alliance, it may share 
characteristics or evoke similar feelings as having a sense of belonging. Therapeutic alliance may 
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even promote a sense of belonging in the patient. Because of these potential connections, it was 
recognized that therapeutic alliance and sense of belonging may have similar and distinct 
influences on adherence behaviors. Similarly, the therapeutic alliance may influence hope and 
even hope may be promoted within the context of this relationship. Therefore, when studying 
adherence in schizophrenia, it will be important to attempt to distinguish between the effects of 
the therapeutic alliance and the patient’s general sense of belonging and hope as well as to assess 
for the degree of covariance of the concepts in relationship to medication adherence. For this 
reason, therapeutic alliance was controlled for in this study. 
Patient-related factors. Lastly, the patient-related factors included insight, attitudes 
towards medication, substance abuse, socio-demographic factors, and illness characteristics 
(Brain et al., 2013; Coldham et al., 2002; Czobor et al., 2015; Gutierrez-Casares et al., 2010; 
Leutwyler et al., 2013; Meier et al., 2010; Misdrahi et al., 2012; D. Novick et al., 2010; Novick 
et al., 2015; Olfson et al., 2000; Quach et al., 2009; Rabinovitch et al., 2013; Sapra et al., 2013). 
One of the most relevant patient factors is substance abuse, which has been repeatedly found to 
be associated with medication non-adherence (Ascher-Svanum et. al., 2006; Coldham et. al., 
2002; Czobor et. al., 2015; Gutierrez-Casares et. al., 2010; Hudson et. al., 2004; Misdrahi et. al., 
2012; Novick et. al., 2010; Olfson et. al., 2014; Rabinovitch et. al., 2013). In a large longitudinal 
study of persons with schizophrenia from multiple states and various treatment settings 
(community and state settings, university health care settings, and Veteran’s Administration 
facilities), multiple factors were studied, and illicit drug use was found to be the top predictor of 
medication non-adherence (OR = 1.8, CI = 1.1-3.0 p =.025). Czobor et al., (2015) found that 
individuals who had substance abuse at baseline were twice as likely to be medication non-
adherent 6 months later (OR = 1.8, p<.0001). The prevalence rates of substance abuse in persons 
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with schizophrenia are high, with as much as 50% lifetime prevalence (Buckley, Miller, Lehrer, 
& Castle, 2008; Volkow, 2009). This high prevalence, combined with findings of associations 
with non-adherence, support a need to report substance use in studies of non-adherence in 
schizophrenia. For this research, individuals who were identified as having current substance 
abuse at study enrollment were excluded from the study. 
Role of sense of belonging and hope in medication adherence in schizophrenia. Two 
factors that have only minimal or nonexistent exploration in schizophrenia but that may be 
related to medication adherence are sense of belonging and hope. While the research on sense of 
belonging and hope in schizophrenia is scant, there are suggestions of potential linkages.  
Exploration of sense of belonging and hope has the potential to contribute new knowledge about 
medication non-adherence in schizophrenia that, if fruitful, could lead to the development of 
invaluable interventions for this problem.  
Loneliness and isolation, the opposite states of sense of belonging, have been identified 
as themes in the lives of persons with schizophrenia, with related feelings of hopelessness and 
decreased QOL (Barut et al., 2016; Davidson, 1997). Humans seem to be hard-wired to be with 
other people; isolation and/or alienation are not only detrimental to overall health but are also 
perceived as being socially unacceptable or otherwise an unfavorable state of being. Although 
limited schizophrenia research exists on sense of belonging, the close construct social support, is 
identified as an area of common deficit in this population (Agarwal et al., 1998; Pyne et al., 
2006) and, as previously identified, has been frequently found to be associated with medication 
adherence. It is important to distinguish that social support and sense of belonging, although 
related, are separate concepts; a person can have adequate social supports in place yet not feel a 
sense of belonging (Barut et al., 2016). Belonging and adherence have been linked in other 
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populations; belonging to a peer support group has been shown to improve adherence in women 
with breast cancer (Tehrani, Farajzadegan, Rajabi, & Zamani, 2011). The linkages in other 
populations, combined with the potential for sense of belonging to account for more variance 
than social support alone, supports the need to study sense of belonging and adherence in 
schizophrenia. 
According to consumers, current literature and health-care policy, hope is central to 
recovery in schizophrenia (P. E. Deegan, 1997; Frese, 2009b; Kylma, Juvakka, Nikkonen, 
Korhonen, & Isohanni, 2006).  Hope has been identified as a positive coping strategy for dealing 
with chronic illness (Herth, 1995; Miller, 1989), and is identified as an important value in 
recovery from schizophrenia and mental illness in general (P. W. Corrigan, McCracken, & 
Holmes, 2001; Substance Abuse and Mental Health Administration, 2006).  Hopelessness, which 
is compounded by stigma, is a common symptom of schizophrenia and a predictor of suicide 
(Chien, Leung, Yeung, & Wong, 2013; Schrank, Bird, Rudnick, & Slade, 2012; Wahl, 2012).  
Research examining the influence of hope on medication adherence, while limited, 
suggests a positive connection (Kukla, Salyers, & Lysaker, 2013). This may be because a 
hopeful attitude supports lifestyle adjustments that promote adherence (Aspeling & van Wyk, 
2008), as well as increasing patient activation and engagement in treatment. A recent qualitative 
inquiry found that hope might be related to treatment adherence (Barut et al., 2016). Hope has 
been found to be significantly correlated with insight into illness, (Kylma et al., 2006; Lysaker, 
Campbell, & Johannesen, 2005), a factor which has been repeatedly linked to medication 
adherence in schizophrenia (E.-M. Beck, M. Cavelti, S. Kvrgic, B. Kleim, & R. Vauth, 2011; 
Brain et al., 2013; Jónsdóttir et al., 2013).  Hope has been linked to adherence in other chronic 
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illnesses (Berg, Rapoff, Snyder, & Belmont, 2007; Makarem, Smith, Mudambi, & Hunt, 2014), 
warranting further exploration in persons with schizophrenia.  
Summary of Findings 
Various environmental, treatment, and patient related factors are identified in the 
literature as contributing to medication adherence behaviors in schizophrenia. The results of 
studies on these factors have yielded inconsistent and often conflicting results with no significant 
impact on the problem. Prevalence rates of medication non-adherence in schizophrenia continue 
to be high with resulting poor patient outcomes, warranting exploration of new factors, such as 
sense of belonging and hope, to understand medication adherence behaviors in schizophrenia. 
Exploration of sense of belonging and hope has potential to provide new understanding of 
positive factors influencing medication adherence in this population. This research may 
subsequently guide future interventional research that will decrease rates of medication non-
adherence. Interventional research is sorely needed because even though the problem has been 
widely studied, there are no consistently effective strategies in place that have had any impact on 
the high prevalence rates (Velligan et. al., 2009). 
Definition of Terms 
Medication Adherence. The World Health Organization (WHO) defines adherence as 
“the extent to which a person’s behavior – taking medication, following a diet, and/or executing 
lifestyle changes – corresponds with agreed recommendations from a health care provider” 
(Sabaté, 2003 p. 3). This dissertation study uses the common definition of medication adherence 
defined as the patient’s report of taking equal than or greater than 80% of prescribed medication. 
This cut-off percentage of adherence is per recommendations by expert consensus guidelines on 
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medication adherence problems in schizophrenia and other chronic and severe mental illnesses 
(Velligan et al., 2009).  
Medication Non-adherence. Medication non-adherence is when a person inaccurately 
takes prescribed medications by increasing or decreasing the dosage, taking medications at 
different times than prescribed and/or failing to take the medication at all (Byerly et. al., 2007; 
Velligan et. al., 2006). Medication non-adherence then will be defined for this research as any 
deviation from the prescribed medication regimen that results in taking less than 80% of 
prescribed medications, as reported by the patient, and includes partial and full non-adherence. 
 Sense of Belonging. Sense of belonging is a vital mental health concept that is closely 
correlated with social and psychological functioning (Hagerty et al., 1992; Hagerty & Williams, 
1999). For this dissertation, sense of belonging will be defined as ‘the experience of feeling 
connected or being a part of something (i.e. relationships or involvement with another person[s], 
group, community, organization, or environment) that makes the person feel as if he or she ‘fits 
in’ or belongs’.   
 Hope. Hope is a multidimensional concept that involves looking toward the future with a 
sense of positive expectation and intentionality. It provides one with a sense that one has a 
future, enables the person to cope with events in the present and encourages the individual to 
uses crises as opportunities for growth. This research study uses a definition of hope whereas 
hope is “a multidimensional dynamic life force characterized by a confident yet uncertain 
expectation of achieving good, which to the hoping person is realistically possible and personally 
significant” (Dufault & Martocchio, 1985 p. 380). 
 Therapeutic Alliance. Therapeutic alliance in the schizophrenia literature has largely 
been defined in terms of the relationship between the patient and a therapist or counselor (Frank 
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& Gunderson, 1990) (Horvath & Greenberg, 1989; Hougaard, 1994; Kvrgic, Cavelti, Beck, 
Rüsch, & Vauth, 2013). This relationship has been described as a ‘helping’ or ‘working’ 
relationship that involves the development of trust and understanding between the patient and the 
clinician and results in better treatment outcomes (Frank & Gunderson, 1990; Kvrgic et al., 
2013). Recent literature suggests that a therapeutic alliance between a prescribing provider and 
the patient is of equal importance, is defined similarly and involves a positive trusting 
relationship (Baloush-Kleinman et al., 2011; Canas et al., 2013; Misdrahi et al., 2012) Canas et 
al., 2013; Misdrahi et al., 2012). For the purposes of this research, a therapeutic alliance includes 
the patient having a generally positive perception of the relationship with his or her prescribing 
clinician in which he or she feels understood and includes drug-taking aspects, psycho-education, 
and the day-to-day relationship with the clinician (Misdrahi et al., 2012). 
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4 CHAPTER 3  
Methodology 
Research Design and Assumptions 
This dissertation utilized a descriptive-correlational, cross-sectional research design. 
Cross-sectional studies are interested in identifying variance in multiple cases at a single point in 
time and have multiple advantages (Bryman, Becker, & Sempik, 2008). One advantage of the 
cross-sectional design for dissertation research is that they are typically less expensive than other 
design types, reduce need to track subjects over time, and enable associations to be made 
between multiple variables without the need to manipulate the study environment or variables of 
interest (Bryman, 2008). The disadvantage of using a cross-sectional design is weak internal 
validity because of inability to identify causal inference or directionality of associations 
(Bryman, 2008). The cross-sectional design merely provides a picture of one point in time and 
takes no consideration of influences before or after that time-point. External validity is also 
restricted, as generalizability is limited to the region and sample characteristics.  
Description of Research Settings 
The study was conducted in community mental health centers (CMHC) located in 
Davidson County, Tennessee and included Park Center, the Mental Health Cooperative (MHC) 
and Centerstone.  
Park Center is a not-for-profit organization that provides psychiatric rehabilitation and 
other supportive services for persons experiencing serious mental illness. Members elect to 
attend the program and work toward their own recovery through employment training, 
educational groups and peer support in an environment that provides a safe and compassionate 
atmosphere to maximize recovery. Park Center primarily serves individuals within Davidson 
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County and surrounding communities. Park Center provided services to 829 persons in 2016, of 
which, 37.9% had a schizophrenia spectrum diagnosis. 
The Mental Health Cooperative serves individuals with serious mental illnesses, 
primarily from Middle Tennessee and from the Southeastern region of the United States. At the 
time of this study, MHC was actively providing care for approximately 10,000 patients, of which 
approximately 3,150 had a diagnosis of a schizophrenia spectrum disorder. MHC also has a 
Program for Assertive Community Treatment (PACT) team which is a person-centered mental 
health service delivery model to promote community living and psychological rehabilitation for 
individuals with severe and persistent mental illness who have not highly benefited from 
traditional outpatient services. During the time period that this research was conducted, the MHC 
PACT team was actively serving approximately 85 patients, of which approximately 60-65 had a 
schizophrenia spectrum diagnosis. 
Centerstone is one of the nation’s largest not-for-profit providers of community-based 
behavioral health care, offering a full range of mental health services in Florida, Illinois, Indiana, 
Kentucky and Tennessee.  As of 2017, Centerstone consisted of more than 50 facilities 
throughout Middle Tennessee. Participants were recruited from two clinics: The Frank Luton 
Center and Centerstone Madison. In fiscal year 2016, Centerstone provided services for 56,119 
adults and children in Tennessee, of which 3,116 adults were diagnosed with a schizophrenia 
spectrum disorder. Research conducted at Centerstone required approval from the Centerstone 
Research Institute (CRI). CRI functions as the research and development arm of Centerstone, 
committed to developing industry-leading science and supporting the provision of the highest 
quality of behavioral health care.  
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Sample and Sampling Plan 
Nature and size of sample. Purposive sampling was used to recruit a convenience sample 
of 65 community-dwelling persons diagnosed with schizophrenia who were between the ages of 
18-65 years. This sample size of 65 participants satisfied the minimal requirements for 
generating stable parameter estimates from the most complex statistical method proposed for 
study data analysis (10 cases per independent variable in a multiple linear regression with 2 
primary independent variables and 1 control variable). A sample size of 65 would achieve 80% 
statistical power to detect a beta coefficient as small as 0.34 which represents 10% shared 
variance (alpha=0.05). Detectable associations of this magnitude represented meaningful clinical 
significance for this study. 
Inclusion/Exclusion Criteria 
 Participants were recruited using purposive sampling based on the following 
inclusion/exclusion criteria:  
Inclusion Criteria:  
1) Primary Diagnosis of Schizophrenia 
2) 18-65 years of age.  
3) English-speaking 
4) Engaged in self-management of oral medications  
Exclusion Criteria:   
1) Current known affective disorder 
2) Current known or self-reported substance abuse 
3) History of documented diagnosis of cognitive impairment  
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4)  Inability to provide informed consent as demonstrated by positive screen of 
the Evaluation to Sign Consent (ESC) 
5) Primary medication for psychosis in a long-acting injectable form. 
6) Receiving Mandatory Ordered Treatment (MOT) by a court of law. 
Rationale for Inclusion/Exclusion Criteria. Participants included individuals with a primary 
diagnosis of schizophrenia and did not include persons who had a current affective diagnosis or 
current substance abuse. This exclusion was to avoid the possibility of these conditions 
influencing the independent variables of sense of belonging and hope.  
The age range of 18-65 was chosen to avoid confounding with unique differences in 
adherence behaviors that may be related to youth or the elderly. Persons who had a history of a 
documented cognitive impairment were excluded due to the possible effects on memory function 
and functioning, as well as to ensure ability to provide informed consent. English speaking 
patients were recruited due to the PI’s limitation of only speaking English and the unavailability 
of the measures in other languages. Patients on long-acting injectable medications for psychosis 
were excluded, as this is a passive form of medication management in which a nurse is 
responsible for medication management and may confound the picture of medication adherence.  
 Recruitment Methods 
Community dwelling persons with schizophrenia were recruited for the study with the 
intent to capture broad socio-economic and ethnic diversity in patients. Recruitment occurred 
through referral from clinicians at the CMHCs. The study recruitment methods were developed 
to ideally gain a sample representative of the population in Davidson County, TN, which is 
roughly 65% Caucasian, 25% African-American, 8% Hispanic, and 2% Asian (US Census 
Bureau, 2015). Subjects were not excluded based on gender or minority status.  
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Informational flyers about the study that provided information about how to contact the 
study team for enrollment screening were made available to potential participants at each of the 
CMHCs. Referring clinicians at the CMHCs were educated about the study by the PI.  Specific 
processes for each site following the study protocol were developed by the PI and study site 
liaisons. The study was conducted in private rooms at each of the community health centers 
respectively. 
Referring clinicians screened medical records to determine if the individual met criteria 
for involvement in the study, and then shared information about the study with identified 
potential participants. Once an individual agreed to be contacted about the study, if it happened 
while a member of the research team was on site, the PI or RA (research assistant) met with the 
potential participant in a private room, provided information about the study, and if indicated, 
perform informed consent. If the participant was consented and screened into the study, he or she 
had the option to complete the study at that time or schedule a time at his or her convenience. If 
the participant expressed interest to the referring clinician at a time when a member of the study 
team was not on site, the referring clinician emailed the PI via secure file with the name and 
phone number of the potential participant. The PI or RA contacted the potential participant and 
shared information about the study. If the person was interested, a time was scheduled to meet 
for further discussion about the study and informed consent, if indicated, was conducted in 
person. These meetings were coordinated to be before or after patients’ clinic appointments if 
possible, or at a time of the person’s convenience. The participant had the option of completing 
the study at that time or scheduling another time to complete the study.  
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Human subjects’ protection. 
After approval by the dissertation committee, approval was received from the Vanderbilt 
University IRB prior to recruitment. Additional approvals were obtained from the Centerstone 
Research Institute and Centerstone administration, from the administration of the Mental Health 
Cooperative, and from the administration of Park Center. Compliance with the study protocol 
was assured through regular meetings with the PI’s faculty advisor, Dr. Sheila Ridner. This was a 
non-interventional study, and participants were believed to be at minimal risk. Potential risk for 
breaches in confidentiality and privacy were mitigated as follows: 1). Patient participation or 
lack thereof was not shared with the clinical team and patient responses to questionnaires were 
not shared with the clinical team. 2). Participants were assigned a random number upon study 
enrollment and all data collection materials were only identified by that number. 3). Electronic 
data maintained on a secure server in a file accessible only by the research team. 4). Documents 
which must necessarily contain subject identifiers (i.e. payment forms and informed consents) 
were stored in a locked filing cabinet accessible only to the PI). Consents and study completion 
occurred in a private room to ensure privacy.  
No direct benefits to participants were anticipated, although some participants did 
indicate that participation in the study was a positive experience. During the interview, some 
questions that dealt with personal or emotional matters were identified as somewhat stressful or 
mildly upsetting to think about for a few study participants.  All subjects were given the option to 
refuse to answer any questions that made them feel uncomfortable.  All interviews and surveys 
were administered by the PI and RA who were trained how to respond to meet the person’s 
needs.  In the few instances where participants became upset during an interview, the participants 
took a break to go to the bathroom or get a beverage and were able to return to the interview 
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without further distress and completed the study. In two instances, subjects made comments 
indicating possible threats to self or others. In both instances, the PI/RA followed the standard 
procedures previously outlined by the respective CMHC for securing subject and staff safety.  
Data Collection Methods 
Procedures 
Potential participants referred by phone or secure email file were contacted by phone, 
informed about the study, and if interested in continuing, were screened using a PI-developed 
screening tool to determine whether they met the inclusion/exclusion criteria. For those referred 
in person at the CMHC, this was done in an interview meeting in a private room. Data was 
entered directly into REDCap (Research Electronic Data Capture). REDCap is a secure web-
based application hosted by Vanderbilt University. REDCap servers are housed in a local data 
center at Vanderbilt, and all web-based information transmission is encrypted (Harris, 2009). 
 If the inclusion/exclusion criteria were met, the PI and/or research assistant met with 
potential subjects in a private room at the CMHC to further provide information about the study, 
and if indicated, conduct informed consent. After informed consent was completed, a screening 
tool, the Evaluation to Sign Consent (ESC) (Resnick et al., 2007) was used to determine if the 
participant continued to fully understand the details and implications of study participation. The 
ESC is a five-item questionnaire that assesses comprehension of information to provide ethically 
valid consent and was originally developed for research in psychiatrically ill individuals 
(DeRenzo, Conley, & Love, 1998; Resnick et al., 2007). (See Appendix A).  
The ESC has been assessed to be an acceptable screening tool for comprehension of 
consent in research of individuals diagnosed with schizophrenia (Beebe & Smith, 2008; Beebe et 
al., 2010). In testing of this instrument, reliabilities of the scores with persons diagnosed with 
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psychiatric disorders were moderate (Cronbach’s alpha = 0.81, test-retest r=0.81) (Resnick et al., 
2007). The ESC was used in this study to screen for comprehension of consent prior to 
enrollment in the study. If subjects were unable to answer the questions in the ESC, they did not 
continue in the study. If the participants were able to successfully complete the ESC they were 
assigned a randomized study ID and then were offered the ability to complete the study measures 
at that time or schedule another time at their convenience.  
The data collection interview lasted between 45 minutes to 1 1/2 hours in duration. 
Participants could self-complete the measures of adherence, sense of belonging, hope, and 
therapeutic alliance using a computer tablet (See Appendices B, C, D, & E).  The PI or RA 
offered to read any of the items for clarification as needed. Some participants expressed feeling 
uncomfortable with the computer tablet or expressed difficulty reading the measures on the 
screen, and the research team member assisted by reading the items, and/or selecting responses 
on the screen as they were identified by the participant. 
 The PI or RA collected additional clinical and demographical data using a structured 
interview tool and the adherence measure. Descriptions of each of these tools follow in the 
section on instruments. 
Data Management. While a random study ID number was assigned to each participant’s 
data record, the PI needed to know each participant’s name during the study to 
coordinate/schedule data collection and random number assignment. A folder was maintained in 
a locked file cabinet in the PI’s office, to which only she had access, with the referral 
information, appointment schedule and participant list. Upon data collection completion, the list 
and folder were destroyed. Electronic data outside of the Redcap database is maintained on a 
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secure server in a file accessible only by the research team. All participant entries into Redcap 
were triple verified by the PI for accuracy and completeness.  
Data Collection Instruments 
Brief Adherence Rating Scale (BARS).  
The Brief Adherence Rating Scale (BARS) is a three-item tool that enquires about the 
patient with schizophrenia’s knowledge of medication regimen and episodes of missed 
medications (see Appendix B). It includes a visual analogue scale to assess the proportion of 
doses taken in the past month (0–100%). The visual analogue scale rating is the final determinant 
of adherence provided by the BARS. The BARS has been assessed to be comparable to 
Medication Electronic Monitoring (EM) devices, which are considered to be the gold standard in 
medication adherence measurement (M. Byerly et al., 2005; M. J. Byerly, Nakonezny, & Rush, 
2008). A significant positive relationship has been found between mean BARS and EM 
adherence (β = 0.98; r = 0.59, p < 0.001) as well as high internal reliability (Cronbach's alpha = 
0.92) (M. J. Byerly et al., 2008). A moderate-to-strong degree of test–retest reliability was also 
found for the BARS (β ranged from 0.53 to 0.92 and r’s ranged from 0.46 to 0.86) (M. J. Byerly 
et al., 2008). For this study, the variable of adherence was dichotomized through use of a greater 
than or equal to 80% adherence cut-off, where medication taking behaviors that were reported as 
taking less than 80% of prescribed medications were categorized non-adherent. This 80% cut-off 
definition of adherence was per recommendations by expert consensus guidelines (Velligan et 
al., 2009).  
 Sense of Belonging Instrument-Psychological State.  
The Sense of Belonging Instrument-Psychological state (SOBI-P) was used to measure 
sense of belonging in this study (see Appendix C). The Sense of Belonging Instrument (SOBI) is 
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a 27-item tool that consists of two separate scales, the 18 item SOBI-P (psychological state) and 
the 15 item SOBI-A (antecedents) (Hagerty & Patusky, 1995). The SOBI-P evaluates the 
experience of belonging, including the experience of feeling valued, needed or accepted and the 
feeling of fitting in with the persons or environment. The SOBI-A is designed to measure 
antecedents, i.e. motivators and potential for sense of belonging to occur and was not used in this 
study. In the original psychometric testing with nursing students, nuns and depressed persons, 
coefficient alphas for the SOBI-P were from .91 to .93 and .63 to .78 for the SOBI-A, with 
correlation between scales at .45 (Hagerty & Patusky, 1995; Hagerty & Williams, 1999). Items 
are rated on a 4-point Likert-type scale from 1- 4; higher scores on the SOBI-P indicate that the 
person experiences a sense of belonging, i.e., that he/she feels valued, needed and accepted 
(Hagerty & Patusky, 1995). 
In the original psychometric testing with nursing students, nuns and depressed persons, 
coefficient alphas were high for the SOBI-P (ranging from r= .91 to .93) (Hagerty & Patusky, 
1995; Hagerty & Williams, 1999). The SOBI-P exhibited moderate test-retest reliability during 
initial testing (Hagerty & Patusky, 1995). Other studies have reported similar coefficient alphas 
for the SOBI-P ranging from .95 to .97 in naval recruits, persons with depression, and traumatic 
brain injury (Bay, Hagerty, Williams, & Kirsch, 2005; Bay, Hagerty, Williams, Kirsch, & 
Gillespie, 2002; Choenarom, Williams, & Hagerty, 2005; Sargent, 2002). The measure has 
limited use in persons with schizophrenia. The full 27-item SOBI was used to test convergent 
validity of a measure of distal support in schizophrenia (Wieland, Rosenstock, Kelsey, Ganguli, 
& Wisniewski, 2007).  
In preparation for this dissertation research, the PI pilot-tested the SOBI-P in a sample of 
20 persons with schizophrenia with a resulting Cronbach’s alpha of .93 (Barut et. al., 2016). In 
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this same study, the SOBI-P exhibited concurrent validity (r =.86) with another measure of 
belonging, the General Belonging Scale (Barut et al., 2016). In this study’s sample, the 
Cronbach’s alpha value for the scores was 0.90. 
 Herth Hope Index (HHI).  
The HHI was adapted from the Herth Hope Scale and consists of 12 items that are rated 
on a 4-point Likert scale with higher scores indicating higher levels of hope (Herth, 1992) (see 
Appendix D). The author of the HHI defined hope as an inner sense of the future, of positive 
expectancy and interconnectedness with self and others (Herth, 1992). 
The initial testing of the HHI in a sample of acutely ill, chronically ill and terminally ill 
patients had a Cronbach’s alpha of .97, with a range of .94-.98 (Herth, 1992) .This measure has 
been extensively used in persons with chronic mental illnesses (Bergin & Walsh, 2005; Bland & 
Darlington, 2002; Carretta, Ridner, & Dietrich, 2014; Chimich & Nekolaichuk, 2004; Patrick W 
Corrigan, Salzer, Ralph, Sangster, & Keck, 2004; Cutcliffe & Barker, 2002; J. R. Cutcliffe & K. 
A. Herth, 2002; Jones et al., 2012). It has also has been extensively used in schizophrenia 
research (Patrick W Corrigan et al., 2004; Landeen, Pawlick, Woodside, Kirkpatrick, & Byrne, 
2000; Littrell, Herth, & Hinte, 1996; Van Gestel-Timmermans, Van Den Bogaard, Brouwers, 
Herth, & Van Nieuwenhuizen, 2010; Yanos & Moos, 2007). This measure has been translated to 
multiple different languages, and the Dutch version has a Cronbach’s alpha of .84 in a general 
sample of persons with serious mental illness that included schizophrenia (Van Gestel-
Timmermans et al., 2010). Consistent with the prior body of work, the Cronbach’s alpha value 
for the scores in this study was 0.86. 
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 Four Point Ordinal Alliance Scale (4-PAS).  
The 4-PAS is a self-rated 11-item questionnaire using a Likert-type rating scale ranging 
from 1 (“strongly disagree”) to 4 (“strongly agree) (see Appendix E). The 4-PAS was developed 
to measure the therapeutic alliance between a prescribing provider and the patient and includes 
medication-taking aspects as well as relationship with the clinician (Misdrahi et. al., 2009). Item 
scores are totaled with higher scores indicating a more positive therapeutic alliance with the 
provider. The 4-PAS was developed from an extensive literature review and adapted from the 
Helping Alliance Questionnaire (Luborsky et al., 1996), which included items specific to 
psychotherapy that were removed for the 4-PAS (Misdrahi et al., 2009).  
Initial testing of the measure was conducted with 92 patients with schizophrenia and 
schizoaffective disorder. Internal consistency was strong (Cronbach’s alpha = .94) (Misdrahi et. 
al., 2009). Principal factor analysis identified two factors: empathy experienced and psycho-
education (Misdrahi et. al., 2009). Concurrent validity was assessed with a participant-rated 
visual analog scale and showed a moderately high association (r-.62, p<.00001) (Misdrahi et. al., 
2009). While it is a newer measure, it has been used in studies beyond the initial testing to assess 
therapeutic alliance in schizophrenia (Hélène, Hélène, Jean, Jean-Marc, & Antoinette, 2014; 
Misdrahi et al., 2012). While other measures exist that have been used in schizophrenia, such as 
the Scale to Assess Therapeutic Relationship – Patient version (Kvrgic et al., 2013), the strengths 
of the 4-PAS in adherence studies in schizophrenia are fourfold: 1) psychometric testing has 
been conducted in schizophrenia 2) the tool was developed for persons with schizophrenia and 3) 
the tool specifically addresses medication-taking and 4) the tool assesses the relationship 
between the prescribing clinician and the patient instead of a therapist as is the case with other 
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tools available. The internal consistency of the scores from this instrument in this dissertation 
sample was consistent with those found previously (Cronbach’s alpha = 0.96). 
Demographic and Clinical Data Collection 
Using a tool created by the PI, information was collected from medical record review and 
patient interview about the participants’ age, diagnosis, gender, marital status, employment 
status, living situation, and type of antipsychotic medication (see Appendix F). 
Data Analysis 
Statistical analysis was conducted using IBM SPSS Statistics software (version 24). Only 
complete responses and measures with randomly missing item responses were used in the 
analysis. Because of the data collection method described above, missing data values were 
minimal. There were no systematic patterns of refusal to respond to questions observed in the 
data collection process.  
Descriptive statistical analysis 
Descriptive statistical summaries were generated for all the study variables. Frequency 
distributions were used to summarize the nominal and ordinal variables. Normally distributed 
data distributions were summarized using mean and standard deviation (SD); skewed 
distributions were summarized using median and inter-quartile range (IQR). Characteristics of 
the two adherence groups were compared using Chi-Square Tests of Independence and Mann-
Whitney tests. When parametric assumptions were not met, as was the case with the BARS and 
the 4PAS, the PI worked with the statistician to conduct the appropriate transformations prior to 
conducting Pearson correlations and linear regression analyses. Both the BARS and the 4PAS 
data were negatively skewed. These data were reflected to a positive skew and the square root of 
the data was taken, which was then found to be normally distributed. The distributions were then 
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reflected back to their original direction for ease of interpretation. Pearson correlations were used 
to assess the extent of the correlations among the covariate and two independent variables: 
4PAS, HHI, and SOBI-P. 
Analysis of Specific Aims 
 Linear and logistic regression models were used to test study hypotheses. The dependent 
variable was the BARS (adherence) overall score. The continuous scores were used in the linear 
regression approach; the clinical dichotomies of adherent/non-adherent per percentile cutoff of 
80% were used in the logistic regression approach. The independent variables in each type of 
regression were the SOBI-P (sense of belonging, Aim 1), HHI (hope, Aim 2). Each of those 
regressions included the 4PAS (therapeutic alliance) as a covariate. A maximum alpha of 0.05 
was used for statistical significance. 
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5 CHAPTER 4 
Results 
Screening and Eligibility 
 Healthcare personnel at the three CMHCs referred a total of 92 individuals to this study. 
Referrals were either in person while the researcher was at the CMHC or were by sharing name 
and contact information by email in a secure electronic file. The study team was unable to 
contact six of the individuals who were referred by email. Per the study protocol, after three 
unsuccessful attempts at making contact by phone, the individual’s contact information was 
destroyed and he or she was not contacted again for study enrollment. Of the 92 referred, 86 
persons were screened for enrollment in the study (See Figure 3). Electronic referrals were 
preliminary screened over the phone and then a full screen was conducted in person.  
 
Figure 3. Study Recruitment and Enrollment 
Of the 86 individuals who were screened for eligibility, 15 were excluded during the 
screening process for not meeting the inclusion/exclusion criteria. Number of individuals 
excluded by reason are listed in Figure 3. The informed consent process, which included 
explanation of the process for screening to confirm informed consent using the ESC, was 
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conducted with 71 participants. One individual declined participation after reviewing the study 
and consent document with the PI. Seventy participants agreed to participate after informed 
consent and comprehension of their consent was evaluated using the ESC. Five people were 
unable to answer one or more questions of the informed consent screening tool (ESC) after a 
maximum of two prompts and were excluded from the study. A total of 65 individuals were 
enrolled and completed the study. 
Sample Characteristics 
Descriptive statistical summaries of this sample of individuals diagnosed with 
schizophrenia (N=65) are shown in Table 1. The sample ranged in ages from 19-65 years with a 
median age of 51. The sample was comprised of 42 (64.2%) males and 23 (35.4%) females. Of 
these individuals, only 7.7% identified as being married or with a partner, while the majority 
(92.3%) identified as being single, divorced or widowed. Over half of these lived in a supervised 
group home (52.3%). The remainder either lived with a family member individuals or friend 
(29.2%) or alone (18.5%). The sample represented a wide range of educational experiences, with 
just over 6% achieving a higher education degree while 40% achieved less than a high school 
education.  
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Table 1. Descriptive Statistical Summaries of the Sample Characteristics (N=65) 
Characteristic  n % 
Gender 
     Male 
     Female 
Race 
     White 
     Black 
     Hispanic 
     Other (Kurdish) 
 
42 
23 
 
33 
30 
1 
1 
 
64.6 
35.4 
 
50.8 
46.2 
1.5 
1.5 
Education 
     Grade School 
     Some High School 
     High School 
     Some College 
     Bachelors  
     Masters 
     Doctorate 
 
11 
15 
7 
18 
3 
0 
1 
 
16.9 
23.1 
26.2 
27.7 
4.6 
0 
1.5 
Marital Status 
     Single/Divorced/Widowed 
     Married/Partner 
Living Arrangement 
     Alone 
     w/Family/Friend     
     Group Home 
Area of Residence 
     City/Urban 
     Country/Rural 
     Suburb  
Employment Status 
     Full-time 
     Part-time 
     Retired 
     Disabled 
     Unemployed 
 
 
Age (years) 
 
60 
5 
 
12 
19 
34 
 
51 
6 
8 
 
3 
6 
1 
44 
11 
 
Median 
51.3 
 
92.3 
7.7 
 
18.5 
29.2 
52.3 
 
78.5 
9.2 
12.3 
 
4.6 
9.2 
1.5 
67.7 
16.9 
 
IQR 
39.5-57.2 
 
Descriptive Summaries of Study Instrument Scores 
Scores from each of the study instruments are summarized in Table 2. Fifty percent of the 
therapeutic alliance (4PAS) scores were between the range of 31.4 and 36.5 within the possible 
range of 11-44.  Adherence ratings per the BARS were high in this study. The interquartile range 
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of adherence (BARS) ratings for this sample was 76-95%, with a median rating of 90%. Both 
hope (HHI) and sense of belonging (SOBI-P) were normally distributed. The mean hope (HHI) 
score on the hope (HHI) measure was 34.6 (SD=5.7) with a total range of 17-45. The scores on 
the belonging measure (SOBI-P) tended to span the middle range of possible scores (mean=44.5, 
SD=9.4), where the maximum total score possible was 72.  
Table 2. Descriptive statistical summaries of the study measures (N=65) 
Measure Median IQR Min-Max 
Therap Alliance (4PAS) 
 
Adherence (BARS) 
33.5 
 
90.0 
 
31.4-36.5 
 
76.0-95.0 
11-44 
 
20-100 
 Mean SD Min-Max 
 
Hope (HHI) 
     
34.6 5.7 17-45 
Belonging (SOBI-P) 44.5 9.4 21-69 
 
 Of the sample of 65 participants, 45 participants (69.2%) were rated as adherent to 
medications. Descriptive statistical summaries of adherent and non-adherent participants are 
shown in Table 3. Adherent and non-adherent participants were very similar across the domains 
of age, gender, race, education, marital status, living arrangements and employment status. There 
were no statistically significant relationships between adherence group and any of these 
variables. 
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Table 3. Descriptive statistical summaries of adherent and non-adherent participants (N=65). 
Characteristic No (N=20) Yes (N=45)  
 n(%) n(%) p-value 
Gender 
     Male 
     Female 
 
14(70.0) 
6(30.0) 
 
28(62.2) 
17(37.8) 
0.545 
Race 
     White 
     Black 
     Hispanic 
     Kurdish 
 
9(45.0) 
10(50.0) 
0(0.0) 
1(5.0) 
 
24(53.3) 
20(44.4) 
1(2.2) 
0(0.0) 
0.395 
Education 
     High School or less 
     Some College 
     College Degree 
 
14(70.0) 
5(25.0) 
1(5.0) 
 
29(64.4) 
13(28.9) 
3(6.7) 
0.904 
Marital Status 
     Single/Divorced/Widowed 
     Married/Partner 
 
17(85.0) 
3(15.0) 
 
43(95.6) 
2(4.4) 
0.140 
Living Arrangement 
     Alone 
     w/Family/Friend     
     Group Home 
 
4(20.0) 
6(30.0) 
10(50.0) 
 
8(17.8) 
13(28.9) 
24(53.3) 
0.964 
Employment Status 
     Full-time/Part-time 
     Retired/Disabled/ 
         Unemployed 
 
3(15.0) 
17(85.0) 
 
6(13.3) 
39(86.7) 
0.857 
Age Median(IQR) 
49.7(39.7-57.2) 
Median (IQR) 
52.4(39.1-57.1) 
 
0.804 
Note: IQR represents the 25th and 75th percentile values. 
 
 
Correlations among the covariate (therapeutic alliance) and the two independent variables 
(hope and belonging) are shown in Table 4. There were no statistically significant correlations 
between therapeutic alliance and sense of belonging, nor between sense of belonging and hope (p 
> 0.05). However, there was a statistically significant association between therapeutic alliance 
and hope (r=0.66, p < 0.001, see Table 4).  
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Table 4. Univariate Correlations among independent variables (N=65) 
Measure 4PAS HHI SOBI-P 
Therapeutic Alliance (4PAS) - 0.66(< 0.001)  
 
-0.08(0.543) 
Hope (HHI) 
 
 - 0.08(0.526) 
Sense of Belonging (SOBI-P)   - 
Note: Values in cells are r (p-value) 
 
 
Aim 1: Associations of Sense of Belonging with Adherence  
Research Question #1: Controlling for therapeutic alliance, is there an association 
between sense of belonging and medication adherence in persons diagnosed with schizophrenia.  
Summaries of the results from both the linear and logistic regressions of the sense of 
belonging scores with medication adherence are shown in Table 5. The unadjusted correlation of 
the SOBI-P scores with the BARS continuous scores was not statistically significant (r=0.12, 
p=0.361). Neither was the correlation of the combination of the SOBI-P and 4PAS scores with 
the BARS statistically significant (R=0.15, p=0.492, adjusted R2 < 0.01). After controlling for the 
slight correlation of 4PAS with BARS, the unique contribution of the SOBI-P was ~1% shared 
variance (beta=0.12, p=0.334, see Table 5).  
There were no statistically significant differences between the SOBI-P scores for the two 
groups created by dichotomizing the BARS score (p=0.134, unadjusted findings Table 5). The 
average SOBI-P score for the adherent group of participants was 45.6 (SD=9.2) while the non-
adherent group mean was 41.9 (SD=9.5). Furthermore, consistent with the use of the BARS as a 
continuous outcome variable, the analysis that included the therapeutic alliance scores with the 
SOBI-P scores was also not statistically significant (p = 0.106, see Table 5).  
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Table 5. Associations of SOBI-P with BARS controlling for 4PAS (N=65) 
 Unadjusted Adjusted 
Measure r p-value beta  p-value 
Therap Alliance (4PAS) 0.09 .487 0.10   .443 
Belonging (SOBI-P)  0.12 .361 0.12  .334 
      
 O.R. p-value O.R. 95% C.I. p-value 
Therap Alliance (4PAS) 1.05 .205 1.06 0.98 – 1.15 .139 
      
Belonging (SOBI-P) 1.05 .143 1.05 0.99 – 1.12 .100 
Linear: Multiple R = .15, p=.492; R2 = .02; Adjusted R2 = < .01   
Logistic: Χ2(df=2) = 4.48, p =0.106 
 
Aim 2: Associations of Hope with Adherence 
Research Question #2: Controlling for therapeutic alliance, is there as association 
between hope and medication adherence in persons diagnosed with schizophrenia? 
Summaries of the results from both the linear and logistic regressions of hope with 
medication adherence are shown in Table 6. The unadjusted correlation of the HHI (hope) scores 
with the BARS (adherence) continuous scores was statistically significant (r=.26, p=.040). The 
model that included therapeutic alliance as a covariate was not statistically significant (Multiple 
R=0.28, p=.084, adjusted R2=0.05). 
The average HHI score for the group of participants classified as adherent on the BARS 
was 35.8 (SD=4.6) which was statistically significantly higher than that of the group classified as 
non-adherent which was 32.0 (SD=7.2, p=.023). Contrary to the continuous BARS findings, an 
analysis that included therapeutic alliance as a covariate was statistically significant (p=0.039). 
There remained a statistically significant increase in the likelihood of being “adherent” using the 
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clinical category with increasing hope (HHI) values (OR=1.16, 95% CI=1.01-1.34, p = 0.038, see 
Table 6).  
 
Table 6. Associations of HHI with BARS controlling for PAS (N=65) 
 Unadjusted Adjusted 
Measure r p-value beta  p-value 
Therap Alliance (4PAS) 0.09 .487 -0.14  .383 
Hope (HHI) 0.26 .040 0.35  .035 
      
 O.R. p-value O.R. 95% C.I. p-value 
Therap Alliance (4PAS) 1.05 .205 0.97 0.87-1.09 0.603 
      
Hope (HHI) 1.13 .023 1.16 1.01-1.34 0.038 
Linear: Multiple R=.28, p=.08; R2=.08 (Adjusted R2=.05)   
Logistic: Χ2(df=2) =6.51, p =0.039 
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6 CHAPTER 5 
Discussion 
Meaning and Significance of Findings 
This chapter presents a discussion of the study results. The objective of this research was 
to study factors influencing medication adherence in persons diagnosed with schizophrenia. 
Despite decades of research, causative factors that can be positively impacted to consistently 
improve medication non-adherence are not well-identified.  In this quantitative study conducted 
in community mental health centers, the researcher sought to understand the possible impact of 
sense of belonging and hope on medication adherence in persons with schizophrenia. It was 
hypothesized that these factors would prove to be meaningful related to medication adherence 
and inform future interventional nursing research. Key findings of this study were: (1) 
sociodemographic variables were not found to be correlated to with medication adherence (2) 
The majority of participants in this study, (69%), were rated adherent to medications. (3) 
Individuals with higher sense of belonging scores did not have higher rates of medication 
adherence. No association or shared variability was found between sense of belonging and 
therapeutic alliance in relationship to medication adherence. (4) Individuals with higher levels of 
hope reported higher levels of medication adherence. Hope was found to be significantly 
associated with therapeutic alliance. When using the clinical categories of “adherent” and “non-
adherent”, the relationship between hope and medication adherence continued to be statistically 
significant after controlling for therapeutic alliance. A detailed discussion of these findings 
follows.  
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Sample Characteristics 
Sample sociodemographic characteristics varied from the general population of the 
geographical region included in the study with an underrepresentation of females (35.4% 
compared 51.8%), underrepresentation of Caucasians (50.8% compared to 65%), 
overrepresentation of African-Americans (46.1% compared to 25%), and underrepresentation of 
Hispanics (1.5% compared to 8%) compared to the population in Davidson County, TN (US 
Census Bureau, 2015). While race was not representative of the region of the study, it may more 
closely mirror the population of persons diagnosed with schizophrenia in the U.S. (Schwartz & 
Blankenship, 2014). In a large study of individuals with schizophrenia (n=2327) that recruited 
participants from six states in the U.S, 52.6% of participants were Caucasian, similar to the 
50.8% in this study (Ascher-Svanum et al., 2006). The disparities in race and gender 
representation may also be related to recruitment occurring in urban location. While 
schizophrenia diagnosis is largely equally distributed across genders (U.S. Census Bureau, 
2015), gender distributions widely vary in the literature. Some studies had a similar percentage 
of male participants as the 64.6% in this study (Ascher-Svanum et al., 2006; Brain et al., 2013), 
other studies ranged from 57.4-85% (Haro et al., 2006; Misdrahi, Llorca, Lancon, & Bayle, 
2002; Quach et al., 2009; Tranulis et al., 2011).   
Participants in this study were slightly older than those of other studies in the literature, 
with a median age of 51. In the aforementioned study, the mean age of participants was 41.7 % 
(Ascher-Svanum et al., 2006) In a large European study with close to seven thousand 
participants, the mean age was 40.2 (Novick, Haro, Suarez, Vieta, & Naber, 2009), and in 
another medication adherence study, the median age of participants was 45 (Brain et al., 2013). 
The slightly older median age in this study may have been related to the presence of young adult 
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programs offered by two of the CMHMCs in this study that were located at different sites from 
where recruitment activities occurred.  
Just over 92% of participants in this study were single, separated or divorced. This 
mirrors an older study where 94% of participants were single, separated or divorced (Agarwal et 
al., 1998) and is similar to a more recent study where 85% of participants were single (Tranulis 
et al., 2011). Other studies had lower rates of single participants with reports of 72.7% (D. 
Novick et al., 2010) and 71.1% (Misdrahi et al., 2002). This high rate of single persons may be 
related to the study recruitment sites being in urban areas that are located near low-income 
housing, which would be more affordable for a single person with easier access to resources such 
as the CMHCs. Alternatively, this could be representative of this population as the comparative 
studies listed were conducted across a span of 6-16 years, and with several studies evidencing the 
higher rate of single individuals. This aligns with and may be related to other research indicating 
that social support is low in persons with schizophrenia (Agarwal et al., 1998; Davidson, 1997; 
Pyne et al., 2006).  
Additional sociodemographic characteristics of this study were similar to those found in 
the literature. Slightly more than 52% of persons in this study lived with someone or lived in a 
group home setting, which was similar to a study in the literature review (Novick et al., 2009). 
Over 50% of participants were unemployed in this study, which is comparable to another 
medication adherence study (Brain et al., 2013). Sixty percent of individuals in this study had a 
high school education or greater, which was similar to several studies (Agarwal et al., 1998; 
Misdrahi et al., 2012), yet was 20% higher than another study in the literature (Ascher-Svanum 
et al., 2006). One of the CMHCs had educational programming to assist individuals to take high-
school equivalency examinations, which may explain the higher levels of education in this 
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research sample. For future studies, it may be useful to collect data regarding the types of 
programming and supportive services available at differing CMHCs to explore the impact of 
these types of programs on demographics and on key variables of interest. 
In summary, this study enrolled a sample of individuals diagnosed with schizophrenia 
who lived in Davidson County, Tennessee or the surrounding areas. This sample was older and 
consisted of a higher percentage of males than the general population of persons diagnosed with 
schizophrenia. These findings may be related to the programming and/or locations of the studied 
CMHC sites. Because these sample demographics are not widely representative of the general 
population of Davidson County, Tennessee or of the United States, generalizability of findings 
are limited to the sites and region studied. To assess the applicability of these findings to the 
general population of persons with schizophrenia, additional studies would be necessary across 
geographic regions, to include urban and rural areas in different states. 
Discussion of Instrument Scores 
BARS (Adherence). Forty-five participants (69.2%) in this study were adherent to 
medications, rated 80% or greater per the BARS tool. This is higher than the rate of adherence 
(52.5%) found by research using the BARS with a similar number of participants (M. J. Byerly 
et al., 2008). The higher rate found in this study could be related to adherence and supportive 
programs at the CMHC sites or regional differences in the sample. The rate of adherence in this 
study is similar to some other studies that used tools other than the BARS to measure objective 
and subjective indicators of adherence with rates of adherence between 71-73% (Brain et al., 
2013; Diego Novick et al., 2010). It is also possible that the findings do not accurately portray 
the participants’ actual adherence level, particularly considering that rates of non-adherence in 
many studies identify lower rates of adherence (Acosta et al., 2009; Coldham et al., 2002; Garcia 
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et al., 2016; Lacro et al., 2002). While the BARS tool has been shown to be significantly 
associated with the gold standard in adherence measurement (electronic monitoring devices), 
with high internal reliability, this is the result of one study (M. J. Byerly et al., 2008), and 
replication of these results are needed. Because the tool relies on self-report of medication taking 
behaviors of the individual and the final adherence core is based on the subjective decision-
making of the rater, additional psychometric testing may be needed to determine if the tool 
reliably measures adherence in schizophrenia.  
 SOBI-P (Sense of Belonging). The SOBI-P was developed to measure the level of 
perceived sense of belonging, with initial testing in nuns, students, and depressed individuals 
(Hagerty & Patusky, 1995). Sense of belonging has not been widely studied in schizophrenia, 
and no studies were found using the SOBI-P in schizophrenia beyond the initial testing by this 
researcher (Barut et al., 2016).  The range of possible scores for the SOBI-P are 18-72, with 
higher scores indicating higher levels of sense of belonging. In this sample, the scores were 
predominantly centered in the lower-middle of the range, with an IQR of 31.5-36.5. This 
indicates that these participants had some degree of sense of belonging, but not strongly so. In a 
study of persons with depression, the SOBI-P mean score was 49.14, while a comparison group 
had a mean of 64.5 (Choenarom et al., 2005). The lower scores for this group, are perhaps not 
unusual, as related concepts, such as experiences of loneliness, isolation and a lack of social 
support, are reported to be commonly experienced in this population (Agarwal et al., 1998; 
Davidson, 1997; Pyne et al., 2006). In this study, the lower scores may be related to the high 
percentage of single individuals, who may not have the social support or sufficient interactions to 
experience a higher sense of belonging. It may also be that sense of belonging is deficit in this 
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population because of impaired social cognition and other symptoms of schizophrenia (Shean & 
Meyer, 2009). 
It is notable that in the preliminary qualitative study by this researcher, most subjects 
spoke of the importance of sense of belonging in their lives, suggesting that this is an important 
construct in this population (jbarut et al., 2016). A common symptom of schizophrenia is 
concrete thinking, and in the aforementioned study, participants were asked directly about their 
sense of belonging, whereas this instrument never directly asks about sense of belonging or uses 
the word belonging in any of the items. It may be that the construct measured by the SOBI-P is 
too vague and abstract for persons diagnosed with schizophrenia. Additionally, individuals with 
schizophrenia may not experience sense of belonging in the broad context of society and in the 
world. These individuals often have few relationships, little in the way of social support, and 
often experience stigma from friends, family and society at large. Notably the SOBI-P has 
multiple questions that specifically target societal acceptance, fitting in with friends, family and 
mainstream society, and having a place in the world. This may not capture the experience of 
sense of belonging in persons with schizophrenia because of the stigmatizing nature of the illness 
and challenges these individuals face socially. In order to understand this construct and the lived 
experiences of belonging identified in the previous study more fully, psychometric testing, 
including factor and component analysis, would be beneficial to determine if the SOBI-P 
effectively measures sense of belonging in persons with schizophrenia.  
 HHI (Hope). The HHI has been widely used in studies with persons diagnosed with 
schizophrenia. The range of scores for the HHI is 12-48. The mean hope score for this sample 
was 34.6, with a standard deviation of 5.7. This is higher than scores noted in other studies in the 
literature that reported these scores with a mean of 22.5 (Littrell et al., 1996) (Littrell, Petty, 
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Hilligoss, Peabody, & Johnson, 2001). This indicates that this sample of older individuals with 
schizophrenia may be more hopeful than the general population of persons with this disorder. 
Again, this could be related to regional differences or programming at the CMHC sites that could 
enhance hope. The higher hope scores may also be related to life-experiences and resilience in 
managing the disorder for individuals who are older and may have had the disorder for a longer 
span of time. This cannot be validated however, as it was not within the scope of this study to 
collect information about site programming and attendance nor was length of time since initial 
schizophrenia diagnosis measured. This would be useful to explore for future studies.   
4PAS (Therapeutic Alliance).  The 4PAS is an 11-item tool with scores ranging from 11-
44. The instrument was developed specifically to measure the relationship between prescribing 
clinicians and persons with schizophrenia and includes interpersonal and medication-related 
aspects of the therapeutic alliance. The interquartile range of scores in this sample fell on the 
higher end of the range of scores, indicating that this group had moderate to strong therapeutic 
alliance with their prescribing clinician. Both physicians and nurse practitioners employed at the 
respective CMHC sites referred patients to this study, but data specific to type of provider was 
not collected. Future studies may seek to understand these relationships by exploring if any 
differences exist in the relationship of physicians or nurse practitioners and their therapeutic 
alliance with patients diagnosed with schizophrenia.  
Discussion of Research Questions 
Research Question #1: Controlling for therapeutic alliance, is there an association 
between sense of belonging and medication adherence in persons diagnosed with schizophrenia.  
 Sense of belonging was not found to be related to either therapeutic alliance or 
medication adherence. It was an unexpected finding that sense of belonging did not have any 
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relationship to medication adherence, particularly since the related concept of social support has 
been found to be strongly associated with medication adherence in several studies (Agarwal et 
al., 1998; Coldham et al., 2002; Gutierrez-Casares et al., 2010; Hudson et al., 2004; D. Novick et 
al., 2010; Olfson et al., 2000; Quach et al., 2009; Sapra et al., 2013).It may be that this sample of 
predominantly single individuals did not have high levels of social support and that may have 
impacted the findings across the sample. Concurrent measurement of sense of belonging and 
social support would be beneficial for future studies to determine the relatedness of these 
concepts as well as any impact on medication adherence. As previously mentioned in discussion 
section on study instruments, it may also be that the SOBI-P is not accurately measuring sense of 
belonging in this particular population. In a previous qualitative study, participants expressed 
that sense of belonging was a valuable component of the human experience and suggested 
linkages to medication adherence (Barut et. al., 2016).  Further research on sense of belonging is 
needed in schizophrenia to better understand what, if any, impact sense of belonging has on the 
illness and outcomes related to treatment.  
Another unexpected finding of this study was a lack of correlation between sense of 
belonging and therapeutic alliance. Hagerty et al (1996) suggested that therapeutic alliance may 
impact sense of belonging. Defining attributes of sense of belonging and therapeutic alliance, 
such as interconnectedness and interpersonal relatedness, suggested possible interrelatedness of 
these two constructs. This was not borne out by this study using the SOBI-P to measure sense of 
belonging. While attributes of therapeutic alliance and sense of belonging may be similar across 
the two concepts, based on the findings of this study, it appears that sense of belonging and 
therapeutic alliance are distinct phenomenon that may be completely independent of each other. 
There was no indication that having a strong therapeutic alliance affected sense of belonging in 
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persons with schizophrenia. It does not necessarily follow that having a therapeutic alliance or 
positive relationship with a healthcare would create a sense of belonging in the world. It would 
be of interest to study this further to identify if therapeutic alliance and sense of belonging retain 
distinct properties with other mental illness populations and other health groups or if there are 
characteristics of how persons with schizophrenia relate to others that create this distinction. 
This study theorized sense of belonging as a proxy for subjective norm, or the experience 
of wanting to engage in behaviors because significant other persons in the individual’s life desire 
that he or she do so, and therefore as driving motivating behaviors which would yield medication 
adherence, in accordance with the Theory of Planned Behavior (TPB). However, this was not 
supported in this study, and it may be that subjective norm and/or sense of belonging are 
expressed differently in persons with schizophrenia related to the cognitive, perceptual and 
relational impacts of the illness. While there is some research using the TPB in schizophrenia 
(Kopelowicz et al., 2007; Kopelowicz et al., 2012), research using the model in this population 
related to adherence is limited. It is possible that the assumptions of TPB concerning subjective 
norm do not operate in the same way in this population and different assumptions and/or models 
are needed. It raises the question of whether there are effects of the disease that create unique 
interactions with the world such that feeling a sense of belonging has a different level of impact 
on the behavior of persons with schizophrenia compared to the general population. Further 
exploration of variables that would impact behavior planning and motivating factors influencing 
medication-taking behaviors in this population are needed to provide further understanding.  
The current study alone does not provide a basis to rule out the potential experiential and 
clinical relevance of sense of belonging for persons diagnosed with schizophrenia. It is possible 
that individuals with schizophrenia characteristically do not have high levels of sense of 
 61 
 
belonging and that sense of belonging is not related to medication adherence, despite the 
previous study’s indication that sense of belonging is important in this population (Barut et al., 
2016). It may be that the symptomology of schizophrenia, including the impact of the disease on 
cognitive, interpersonal and social functioning impacts how the person experiences sense of 
belonging. Further phenomenological and experiential exploration of the concept of sense of 
belonging in schizophrenia is needed to better understand the role of sense of belonging in the 
lives of these individuals.   
Research Question #2: Controlling for therapeutic alliance, is there as association 
between hope and medication adherence in persons diagnosed with schizophrenia? 
Hope is identified in both clinical and research literature as being an extremely relevant 
factor in the health of persons with mental illness, and in schizophrenia specifically (Chien et al., 
2013; Corrigan, 2006; P. Deegan, 1994; Frese, 2009a; Kylma et al., 2006; Substance Abuse and 
Mental Health Administration, 2006; Wahl, 2012). This was mirrored in this study; hope was 
found to be significantly associated with both medication adherence and therapeutic alliance in 
persons with schizophrenia.  
After controlling for the significant contribution of therapeutic alliance, hope no longer 
had significant explanatory value on medication adherence using the continuous variable of 
percent of adherence. It is notable that this overall group had a high range of therapeutic alliance, 
and that while most participants were adherent, the range of adherence was from 20% to 100%. 
The high levels of therapeutic alliance combined with a wide range of adherence scores could 
have influenced this finding. For the purpose of this study, and per expert consensus guidelines 
(Velligan et al., 2009) the clinical categories of adherence, where taking 80% or greater of 
medications prescribed equals adherence, have more clinical relevance to practice. When 
 62 
 
comparing adherent versus non-adherent groups per this definition of adherence, those identified 
as adherent tended to have more hope than those who were non-adherent to medications. Using 
the clinical categories, after controlling for therapeutic alliance, participants with higher hope 
values were increasingly likely to be adherent to medications (p=0.039).  Intrinsic and/or 
extrinsic factors may be present in the more hopeful individuals that resulted in higher rates of 
adherence to medications. It is also possible that there are other factors that are influencing the 
medication-taking behaviors that then results in medication stabilization and decreased 
symptoms of schizophrenia, thereby causing the individuals to experience more hope. 
Longitudinal studies of hope and adherence over time may yield more explanatory information 
about these differences. 
The Theory of Planned Behavior model was chosen for this study because of its strength 
in targeting attitudes, such as hope, to influence desired behavior. Attitudes have been shown to 
impact medication adherence in persons with schizophrenia (E. M. Beck, M. Cavelti, S. Kvrgic, 
B. Kleim, & R. Vauth, 2011; Brain et al., 2013; De las Cuevas & Peñate, 2015). There is a 
moderate amount of literature on hopelessness, but the literature on hope in schizophrenia is 
limited, particularly literature exploring hope and medication adherence. Because hopelessness is 
a common symptom of schizophrenia, hope may be more meaningful to these individuals when 
it is experienced. Hope may result in positive experiences and support personal choices that 
enhance engagement and adherence to treatment. Additional understanding is needed to 
understand how individuals with schizophrenia experience hope, as well as how hope influences 
their adherence to medications and other treatment. This will aid development of interventional 
research to help to determine how clinicians can positively affect hope specifically with the aim 
of increasing medication adherence.   
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In the univariate correlations, therapeutic alliance was strongly correlated with 
medication adherence (p<0.001) and with hope. The multivariate correlation showed that hope 
was no longer statistically significant after controlling for therapeutic alliance, indicating that 
hope and therapeutic alliance may have shared aspects that influence medication adherence. 
There are multiple characteristics of the therapeutic alliance to consider that may be impacting 
these relationships. These include having a trusting relationship, effective communication, 
consistency and reliability of the relationship to name a few (Haddad, Brain, & Scott, 2014). Any 
and/or all of these factors combined may be important factors in improving hope and/or 
medication adherence. Further study is needed to evaluate how to leverage the therapeutic 
relationship to increase hope and medication adherence in this population. 
Strengths and Limitations of the Study  
This research is the only known quantitative study exploring the role of hope and sense of 
belonging on medication adherence in persons with schizophrenia. As such, the study contributes 
invaluable information to the extensive body of research on this ongoing dilemma of medication 
non-adherence in this population. A strength of this study is the conceptualization of these 
existential factors as potential factors influencing medication within the framework of the Theory 
of Planned Behavior, particularly related to hope and attitudes. This research targets insights and 
attitudes, both of which have consistently been shown to impact medication adherence in 
schizophrenia. The findings of this study advance the body of literature on medication adherence 
in schizophrenia in a way that has not been previously conducted and illustrates that having an 
attitude of hope is, in fact, related to medication adherence in persons diagnosed with 
schizophrenia. Additionally, it identifies that persons who are not adherent to medications have 
lower levels of hope compared to individuals who are adherent to medications. 
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Another strength of this study is related to specific aspects of the study instruments. Both 
the measure for therapeutic alliance (4PAS) and for medication adherence (BARS) were 
specifically developed for use in persons with schizophrenia. The hope instrument (HHI) was 
initially tested with persons with depression but has been used extensively in various mental 
illness and health states. Additionally, the HHI was developed over two decades ago, and has 
been in use since that time (Herth, 1992).  
A third strength of this study is the referral and screening process. Participants were 
initially screened by their clinician at the CMHC using the inclusion/exclusion criteria. 
Clinicians were provided education on the screening and referral process by the PI, and only 
referred individuals who were identified as meeting the inclusion/exclusion criteria. To preserve 
anonymity of the individual, clinician information was not recorded, and the study team did not 
have access to the medical record of those referred to the study. The study team then conducted a 
thorough screen. If conditions were met, the individual was further screened for comprehension 
of informed consent before enrollment in the study occurred. This is of particular importance, as 
cognitive impairment, which can include comprehension and decision-making ability, is a 
common occurrence in persons with schizophrenia. This screening process provided an 
additional human subjects protection for this vulnerable population.  
A weakness of this study was the use of two instruments (SOBI-P and HHI) with limited 
validity and reliability testing in persons with schizophrenia. The SOBI-P has evidence of good 
reliability and validity in other studies, and preliminary data suggested similar high reliability in 
persons with schizophrenia; however extensive psychometric testing with this instrument in 
schizophrenia has not been conducted. While the HHI has extensive history, has been widely 
used in schizophrenia, and has high reliability in other mental illness populations, no 
 65 
 
psychometric testing data is available specifically in schizophrenia beyond the reliability 
findings in this study.  
Other potential areas for concern include bias, issues of self-report of key variables, and 
lack of use of objective measures. The subjects completed the study measures, and if an 
individual had challenges reading the measures, the PI offered to read the questions aloud and 
either obtained verbal responses or the subject chose his or her response on the tablet screen. 
This introduced a risk of administration bias. There was also a risk of social responsiveness bias. 
Since the researcher was present as the subject completed the instruments, it is possible that 
some participants could have responded in what he/she believed was the expected response. The 
following steps were taken to minimize these risks and the impact on the findings: (1) the 
researcher was diligent in informing the subjects of the study purpose and objectives and to ask 
the questions in a neutral tone and manner, (2) participants were encouraged to make the item 
selections on the tablet themselves whenever possible and (3) the RA was also thoroughly 
trained to administer measures in the same manner as the PI.  
Other limitations of this study include the small sample size and the restriction to 
community mental health centers in one region of a metropolitan area. This limits 
generalizability of the findings, as rural areas and regions outside of the Nashville Metro area 
were not included in this study. Moreover, it is possible that non-adherent participants declined 
to participate upon hearing of the study from the community mental health clinic and therefore 
were never referred to the study. The participants were also not stratified by research site. 
Knowing the research site may have provided key insights into the high degree of adherence of 
this sample. The different community mental health centers had different programs available, 
such as Psychiatric Assertive Community Treatment teams, group therapy and other programs 
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that may have influenced the high rate of adherence, which is not representative of the general 
population of persons with schizophrenia based on the current literature. However, due to the 
small sample size, stratifying the sample by site had the potential to increase risk of loss of 
confidentiality and the sample was not large enough to control for possible variances by services 
offered at each CMHC. Lastly, data was not collected about length of diagnosis or treatment 
specifics such as duration of treatment or type of medication (typical/atypical antipsychotic). 
This information might have yielded important additional insights into the rates of high hope and 
medication adherence in this study. 
Implications for Nursing 
 The significant findings of this research hold meaningful new knowledge that can benefit 
the practice of mental health nursing for both the bedside and the advance practice nurse. First, 
the study clearly illustrates that the therapeutic alliance between clinician and patient can 
significantly impact the medication adherence of patients diagnosed with schizophrenia.  The 
most effective intervention in the psychiatric nurses’ toolbox is the ability to quickly and 
effectively build a therapeutic relationship that builds trust and is a reliable and consistent force 
in the lives of their patients (Dziopa & Ahern, 2009; Peplau, 1997). Secondly, this study 
identified a significant positive relationship between hope and medication adherence. Nurses can 
improve hope in the lives of the individuals diagnosed with schizophrenia by providing nursing 
care that embraces the totality of the person’s human experience within the context of the 
therapeutic relationship (J. Cutcliffe & K. Herth, 2002). This relationship can enable the nurse to 
provide a reflective mirroring for individuals that validates their worthiness as a person and 
inspire hope for a meaningful future. Additionally, within this relationship of trust the nurse can 
provide the patient with education about strategies to manage their illness, including information 
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targeting medication-taking behaviors and benefits of medications. These nurse-led interventions 
can inspire hope that symptom management is possible and that patients can lead productive and 
purposeful lives. This inspiration of hope within the specific and individual context of the 
person’s life and the therapeutic alliance with the nurse may increase medication adherence and 
improve outcomes. 
 Medication non-adherence is a very significant problem for individuals diagnosed with 
schizophrenia and impacts human suffering for these patients and their families. Not only does 
medication non-adherence decrease quality of life for these individuals, it also increases the risk 
of relapse and serious short and long-term impacts on health for individuals and families. 
Medication adherence leads to improved outcomes and is the only consistently identified 
protective factor for suicide. Nurses have a responsibility to improve these outcomes, and 
specifically to focus on strategies that will improve the therapeutic alliance with the patient while 
inspiring hope within the patient such that medication adherence can be improved for these 
individuals. 
Recommendations for Future Research 
 This study presents new findings relevant to the body of literature on medication 
adherence in persons diagnosed with schizophrenia. The literature to date has identified many 
factors that may influence non-adherence, such as substance abuse, poor social support, lack of 
insight, among others. Despite decades of research on the subject, factors that can be influenced 
to consistently improve medication adherence has not been identified. This is the first known 
study to examine the relationship between hope and medication adherence, and the results are 
promising for the potential ability to influence this existential factor and thereby improve 
medication adherence. Additional studies are needed to validate these findings across a wider 
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geographic region and with a larger number of participants. If the findings within this study 
regarding hope are replicated, additional research will be needed to develop and trial 
interventions that nurses and other clinicians can employ to improve hope within these 
individuals. Hope has been anecdotally supported as being profoundly important to mental health 
in individuals experiencing acute mental illness by experts, mental health agencies and the 
literature (P. E. Deegan, 1997; Kylma et al., 2006; Substance Abuse and Mental Health 
Administration, 2006). Linking hope to outcomes in schizophrenia offers the opportunity to 
create a new avenue for exploratory and interventional research across other chronic mental 
illnesses. 
 Therapeutic alliance, which has been studied related to medication adherence with 
evidence of positive effect. This study is unique in that therapeutic alliance was identified as 
potentially influencing both relationships of hope and sense of belonging with medication 
adherence. While therapeutic alliance was not significantly correlated with sense of belonging, it 
was significantly correlated with both hope and medication adherence using. Using the clinical 
categories of adherence, after controlling for therapeutic alliance, hope continued to contribute 
unique significance to whether or not a person adhered to his or her medications. Additional 
research is needed to explore the relationship between hope and therapeutic alliance to determine 
how to best leverage the clinician in the lives of these mentally ill individuals in such a way that 
will consistently improve their lived experience and positively impact outcomes. It may also be 
useful to conduct research exploring similar variables to hope, such as optimism, inspiration, 
motivation, agency, sense of purpose and/or perceived control to help identify strategies that may 
be useful to aid clinicians in improving hope. 
While the findings in this study did not discover significant relationships between sense 
 69 
 
of belonging and medication adherence in persons diagnosed with schizophrenia, it clearly 
identifies the need to further study the phenomenon of sense of belonging in this population. One 
previous qualitative study indicated that the SOBI-P had face validity in persons diagnosed with 
schizophrenia, with indications that it holds clinical relevance for this population (Barut et. al., 
2016). Additional qualitative studies are needed to explore the societal context and personal 
experience of sense of belonging in the lives of persons diagnosed with schizophrenia. In the 
1950’s Abraham Maslow identified a hierarchy of basic human needs that included love and 
belonging needs as central to human health and happiness secondary after physiological and 
safety needs (Maslow, 1954). Self-determination theory proposes a similar basic psychological 
need, relatedness, or the need to feel connected to others, as a requisite to health and quality of 
life (Ryan & Deci, 2000). Social inclusion, being a part of something, and feeling as if one 
belongs, are identified as important to health, particularly mental health (Anant, 1967; Hagerty et 
al., 1992) (M. Lambert et al., 2004). Feeling as if one belongs enhances meaning in life, another 
vital construct to health and well-being (M. Lambert et al., 2004). The terms ‘sense of 
belonging’, ‘need to belong’, and ‘belongingness’ are used interchangeably in the literature to 
describe this favorable state, but while the construct is widely deemed to be important to mental 
health, it lacks definitiveness both in conceptualization and in measurement. 
The SOBI-P needs further psychometric testing and factor analysis in individuals with 
schizophrenia to determine if it is a valid tool for use in this population. Lastly, it would be 
beneficial to conduct research in schizophrenia explore constructs that may be related to sense of 
belonging such as social support, relatedness, and interconnectedness, for example. In the 
original testing of hope instrument used in this study, the factor analysis revealed a third factor of 
hope as “interconnectedness with self and others” (Herth, 1992 p. 1256). Considering the 
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significance of hope found in this study using the HHI, it may also be useful to explore factors 
within the concept of hope as potentially aiding understanding of the concept of sense of 
belonging in this population.  
This study used the Theory of Planned Behavior as a conceptual model to support 
understanding of attitudes and subjective norm influences on medication adherence behaviors. 
Kopelowicz et al (2007) used the model in a study of medication adherence in Mexican 
American adults with schizophrenia, but other studies using the model are limited in this 
population. Future studies may benefit from model testing of the Theory of Planned Behavior to 
determine if it is useful in helping to explain behaviors in schizophrenia. Qualitative studies 
would also aid understanding of the experience of subjective norm in this population.  
 This study used a screening tool to confirm participants’ understanding of 
informed consent. Persons with schizophrenia may have a higher degree of impaired decisional 
capacity compared to other well individuals, indicating a need for evaluation of informed consent 
in research (Appelbaum & Redlich, 2006).  The ESC was used in this study to protect these 
subjects who may be vulnerable due to the neuropsychological effects of their illness. Future 
studies, not only on medication adherence, but other research with individuals diagnosed with 
schizophrenia should consider use of the ESC screening tool, or a similar tool tested in 
schizophrenia, to protect this population. 
In conclusion, this study identifies multiple areas whereupon further exploration is 
needed related to improve understanding of how hope and therapeutic alliance can improve 
medication adherence. Research is needed to develop nurse-driven interventions that instill hope 
and potentially increase adherence.  Further inquiry is also needed regarding the role of the 
therapeutic alliance in increasing hope and improving medication adherence in persons with 
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schizophrenia.  Research that expands on the findings of this study can hopefully lead to 
improvements in medication adherence and, as a result, improve quality of life and meaningful 
lived experiences for this population of chronically mentally ill individuals.  
Lastly, additional research is needed to understand sense of belonging in persons with 
schizophrenia. Sense of belonging is acknowledged as a psychological need and motivator of 
social behavior and is a crucial factor of healthy psychological and social functioning (Anant, 
1967; Hagerty et al., 1992; N. M. Lambert et al., 2013; Maslow, 1954). Further exploration of 
this concept may yield a more refined definition and measurement that will allow future research 
to improve psychological and social functioning in the population of persons diagnosed with 
schizophrenia.  
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